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Projekt je zaměřen poznání souvislosti mitochondrialních patofyziologických 
procesů s psychopatologickými příznaky při bipolární afektivní poruše (BPD). 
Změny aktivity vybraných složek dýchacího řetězce a celková respirační rychlost 
byly měřeny u pacientů s bipolární afektivní poruchou v porovnání s kontrolní 
skupinou. byly použity diagnostické dotazníky, respirometrie s vysokým 
rozlišením a metody radiochemické a spektroskopické. Analýzy provedeny u 21 
zdravých kontrol a 37 osob s diagnózou bipolární afektivní poruchy (F31). 
Statistická analýza zahrnovala parametrické a neparametrické analýzy, faktorovou 
analýzu, jednocestnou analýzu rozptylu a lineární regresní analýzu. Získané 
výsledky ukázaly velkou roli buněčné energetiky v patofyziologii bipolární 
poruchy. Mírný rozdíl mezi různými aktivitami mitochondriálních enzymů byl 
získán u pacientů s manickou a depresivní epizodou onemocnění. Byly také 
prokázány změny mitochondriálního dýchání u pacientů s BPD ve srovnání se 
zdravými kontrolami. Mitochondriální respirační indexy u pacientů v remisi ve 
srovnání se zdravými kontrolními osobami byly změneny v souvislosti s předchozí 
fází onemocnění. Byla zjištěna souvislost mezi stavem onemocnění, 
psychopatologickými příznaky, klinickým zlepšením a mitochondriální patologií. 
Byla stanovena doba trvání mezi akutním manickým stavem a remisí a její 








This study investigates the connection between different pathophysiological 
processes in mitochondria and psychopathological symptoms in patients with 
bipolar disorder. Changes in activity of selected components of the respiratory 
chain and overall respiratory rate of mitochondria were analyzed in patients with 
bipolar disorder when compared to healthy controls. Diagnostic scales and 
questionnaires, high-resolution respirometry, radiochemical and spectroscopic 
methods were used. 37 patients with a diagnosis of bipolar disorder (F31) and 21 
healthy volunteers were involved in the study. Statistical analysis included the 
methods of parametric and nonparametric analysis, factor analysis, one-way 
analysis of variance and linear regression analysis. Obtained results revealed that 
cellular energetics plays a great role in the pathophysiology of bipolar disorder. 
There was a mild difference between different mitochondrial enzymes activity in 
patients within manic phases and depressive phases of the disease. Changes in 
mitochondrial respiration in patients with BD as compared to healthy controls were 
also shown. Mitochondrial respiration indexes for patients with BD in remission as 
compared to healthy controls were altered in accordance with the previous phase of 
the disease. Association between the state of the disease, psychopathological 
symptoms, clinical improvement and mitochondrial pathology was established. 
The duration period between the acute manic state and remission and its 


































Mental disorders are a big group of complex and serious diseases affecting 
mainly the psychic sphere and are characterized by a high prevalence, difficulties 
with the diagnosis, high levels of disability and mortality, a significant societal cost 
and different serious risks for the patients.  
During the last decades many publications revealed an increasing need for 
further research on this topic because of characteristics such as frequent life-
threatening conditions, urgent intervention requirement, clinical pathomorphosis, 
prolonged duration and a delayed treatment response postulate a problem of mental 
disorders as one of the central problems of modern psychiatry and general medical 
practice. Psychopathological symptoms also often cause a significant impairment 
of social functioning which may have an irreversible affect on patient’s life. 
Although research is ongoing many important questions still remain open. 
Questions of early diagnosis and prevention, clinical assessment of the symptoms, 
therapeutic approaches and pathomorphological mechanisms undermining the 
disease continue to be unanswered. One of these questions is a comprehensive 
study of typical pathogenetic features associated with the psychopathological 
symptoms of the disease, including cell mechanisms.  
Cell respiration in psychiatric disorders had been a subject of large research 
interest for many years as the nerve tissue is highly dependent on oxidative 
metabolism because of a high energy demand and thus the brain is extremely 
vulnerable to an insufficient ATP production. Many researchers found evidence for 
mitochondrial dysfunction and oxidative stress in different mental disorders, 
although most of the patients do not have any ‘classical’ mitochondrial disease.   
Mood disorders are one of the main focuses in mitochondria-related research  
since 2000 when Dr. Kato offered a mitochondrial hypothesis based on the 
findings that patients with bipolar disorder have an abnormal energy metabolism 
and abnormal mitochondrial DNA in the brain. 
Mood disorders (depressive, manic and bipolar disorders) are very common 
illnesses, often with recurrent or chronic courses. Their pathophysiology is not yet 
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well known. There is currently no reliable biochemical, genetic, physiological or 
other biological test to diagnose bipolar affective disorder or to predict the success 
of pharmacotherapy.  
The etiology of mood disorders, including BPD, remains uncertain. Both 
genetic background and environmental factors, such as stressful life events or 
substance abuse, are related to the risk of development of BPD (Uher R, 2014). 
Insights into the processes underlying neuroprogression in BPD have been 
provided by studies examining genetic and epigenetic changes, structural and 
functional changes in the brain, damage in neuronal circuits, disturbed circadian 
rhythms, changes in immune and endocrine systems, impairment in neuronal 
plasticity and resilience, increased apoptosis, disturbances of synaptic transmission 
and signal transduction, activation of neurotoxic mechanisms, and changes in 
neurogenesis (Berk M et al, 2014). Pathways underlying neuroprogression in BPD 
include the dopaminergic system, inflammatory cytokines, oxidative and 
nitrosative stress, mitochondrial dysfunction and endoplasmic reticulum stress, 
alterations in cAMP response element-binding protein (CREB) and neurotrophic 
system, dysregulation of calcium signaling, neuroin- flammation, autoimmune 
processes, tryptophan and tryptophan metabolites, and hypothalamic–pituitary–
adrenal (HPA) axis dysregulation. (Berk M et al, 2011;  Anderson G, Maes M, 
2015; Andreazza AC, Young LT, 2014) 
Research for biological markers of bipolar affective disorder is based on a 
current mood hypothesis that the activity of monoaminergic neurotransmitter 
systems, energy cell metabolism, growth factor and other components affecting 
neuronal plasticity.  Nerve cells need an extraordinarily large amount of cellular 
energy to provide for the synthesis of molecules that allow them to receive, process 
and transmit information, develop axonal and dendritic branches, and create new 
synaptic connections. Therefore, the hypothesis of mitochondrial dysfunction is a 
prospective hypothesis for a number of diseases including bipolar affective 
disorder. 
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The aim of the following research is to determine the connection between 
selected mitochondrial functions and psychopathological symptoms during the 





2. Literature review 
 
2.1. Mitochondria, its structure, role and functions 
 
Mitochondria were discovered more than 100 years ago and were then 
viewed as a cytoplasmic element with undetermined functions. Between discovery 
and the 1950s, some observations of mitochondria in ultra thin sections were made 
via the development of the electron microscopy. In the following decades the 
mitochondria structure and biochemical processes taking part in it were thoroughly 
explored. Most research was reduced to the energy production and to different 
changes of mitochondrial structure during the respiration cycle.  
During the last decades we have wintessed a change in the approach to 
mitochondria. An old idea from our textbooks, postulating mitochondria as an 
‘energetic station‘ of the cell is now changing to a kind of ‘Pandora’s box‘ 
hypotheses, which gently suggests that mitochondria take part in various processes 
through various mechanisms. Some components of mitochondria and their impact 
on men’s health are still to be investigated (DiMauro S, Andreu AL, 2000).  
According to the previous paradigm, the role of mitochondria in different 
pathologies and diseases was limited by the description of energy supply 
dysregulation of cell respiration, either in terms of hypoxic and toxic damage or in 
genetic impairment (DiMauro S, Hirano M, 2009). Now so-called ‘side processes‘ 
of mitochondria are coming to the stage. Many studies of mitochondria and its role 
in the pathogenesis of various diseases are being done. Such terms as 
‘mitochondrial pathology‘ and ‘mitochondrial disease‘, having appeared not long 
ago (Luft R, 1994), are also changing their meaning to include a broader range of 
disturbances and lesions. One thing still seems unarguable - mitochondria 
dysfunction is causing diverse effects within the cell and in whole organism 
(Nunnari J, Suomalainen A, 2012).  
Mitochondria are a small cell organelles with two membranes, mostly not 
contacting each other. The outer membrane of mitochondria (7 nm thickness) is 
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smooth, built of proteins and two layers of lipids. It separates mitochondria from 
the cell cytoplasm and provides the transport of small molecules and ions; it also 
has such enzymes as monoaminoxidase, monooxygenase, acyl-CoA (coenzyme A) 
synthase and phospholipase A.  
The inner membrane is plicated and forms numerous folds (cristae), which 
significantly increases the surface area. It contains cardiolipine and proteins, and 
does not have any transport pores. ATP-synthase molecules are located on its 
matrix side. There are also some respiratory chain components in this membrane, 
filling the membrane space.  
Between outer and inner membrane there is an intermembrane space (10-20 
nm thickness). One protein is located in it is cytochrome c, a respiratory chain 
component. 
The internal space of the mitochondria is called matrix. Located in matrix 
enzyme systems of pyruvate and fatty acids oxidation are enzymes of tricarboxylic 
oxid cycle (Krebs cycle), DNA, RNA and protein-synthetizing systems.  
 
Fig. 1. Structure of the mitochondria 
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Mitochondria serve many functions, but their primary goal is participation in 
biochemical cycles of cell respiration. The main processes taking place in 
mitochondria are: the tricarboxylic acid cycle, fatty acids oxidation, carnitine 
cycle, electron transport in the respiratory chain (via I-IV enzyme complexes) and 
oxidative phosphorylation (V enzyme complex). 
  
 
Fig. 2. Mitochondrial function is at the nexus of several pathways that regulate 
synaptic plasticity and cellular resilience.  (Manji H.K. et al, 2012) 
 
2.2. Tricarboxylic acid cycle 
 
Tricarboxylic acid cycle (TCA, Krebs cycle) is the key stage of cell 
respiration; a crossway of several metabolic pathways and an intermediate point 
between glycolysis and respiratory chain. Its role is not only energetic, it is a 
significant source of the precursors’ molecules for synthesis of many important 
compounds. 
A cyclical biochemical process takes place in mitochondria, in which one 
molecule of acetyl-CoA is completely oxidized into two molecules of carbon 
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dioxide (CO2) with reduced form of nicotinamide adenine dinucleotide (NADH) 
(from nicotinamide adenine dinucleotide, NAD+), reduced form of flavin adenine 
dinucleotide (FADH2) (from flavine adenine dinucleotide, FAD) and guanosine-5'-
triphosphate (GTP) production (from guanosine diphosphate, GDP, and inorganic 
phosphate, Pi) (Krebs HA, Weitzman PDJ, 1987). Electrons from NADH and 
FADH2 are transported to the respiratory chain where ATP is formed. 
 
 
Fig. 3. Tricarboxylic acid cycle 
 
Acetyl-CoA, a substrate for the Krebs cycle, is derived from carbohydrates, 
fats, and proteins; in the brain it comes mostly from the glycolysis reaction, where 
glucose is converted to pyruvate, followed by pyruvate decarboxylation by 
pyruvate dehydrogenase complex. The second resource of acetyl-CoA in the brain 
is fatty acids oxidation. 
The cycle consists of several basic reactions. First, two-carbon acetyl group 
of the acetyl-CoA is transferred to a four-carbon acceptor (oxaloacetate) and a six-
carbon compound (citrate) is formed. Two carboxyl groups from oxaloacetate are 
later being lost as CO2, and the missing parts are being donated by acetyl-CoA. 
The loss of donated carbons requires several turns of the cycle, as it is continuously 
supplied by the new acetyl-CoA as a carbon donator (Jones RC  et al, 2000).  The 
energy of the reactions is transferred as electrons to form NADH and FADH2, or to 
other metabolic processes. 
Steps  
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1) Aldol condensation reaction catalyzed by a citrate synthase enzyme 
 
Fig. 4. Tricarboxylic acid cycle, step 1 
 
A methyl group of the acetyl-CoA is attached to the carbonyl group of the 
oxaloacetate. During this reaction an intermediate compound is formed. It is 
quickly hydrolyzed and splits into a free CoA and citrate, which is eliminated from 
the enzyme active point. This reaction is highly exergonic because of hydrolysis of 
the thioether compound, and this negative energy change is necessary for the cycle 
management, because oxaloacetate concentration in the cell is quite low. CoA from 
this reaction takes part in the oxidative decarboxylation of the next pyruvate 
molecule. 
2) Dehydration-hydration reaction catalyzed by aconitase 
Aconitase is an enzyme that contains of FeS-claster and catalyzes a 
reversible dehydration of citrate into an intermediate compound, a tricarbozylic 
acid named cis-Aconitate, which does not leave the active point of the enzyme 
normally. The enzyme attaches a water molecule to the olefinic link of cis-
Aconitate and the reaction goes in two different ways, with a citrate (app. 90%) 
and isocitrate (app. 10%) as its main products. 
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Fig. 5. Tricarboxylic acid cycle, step 2 
 
3) Isocitrate oxidation and decarboxylation reaction 
This step contains of two stages. The first stage is oxidative decarboxylation 
of isocitrate catalyzed by isocitrate dehydrogenase which requires proton transfer 
from NAD+ (or NADP+). At the end of this stage oxalosuccinate is formed. It is 
an intermediate compound and it does not leave active point of the enzyme. The 
second stage involves an interaction between carbonyl group of oxalosuccinate and 
Mn2+ (or Mg2+) ion of the enzyme which pulls the electron density so that α-
Ketoglutarate can be formed. Isocitrate dehydrogenase exists as two izoenzymes, 
eukaryotic cells that have mostly NAD+ dependent izoenzyme. 
 
Fig. 5. Tricarboxylic acid cycle, step 3 
 
4) α-Ketoglutarate oxidative decarboxylation reaction 
This reaction is catalyzed by α-ketoglutarate dehydrogenase which is a 
complex enzyme containing 3 sub-enzymes with several co-factors. This enzyme is 
largely similar to pyruvate dehydrogenase and the whole reaction is almost 
identical to pyruvate oxidative decarboxylation.  
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During the oxidative decarboxylation succinyl-CoA is formed. NAD+ 
behaves as an electron acceptor and CoA transports the succinyl group. 
 
Fig. 6. Tricarboxylic acid cycle, step 4 
 
5) Substrate-level phosphorylation reaction 
Succinyl-CoA has a thioesher bond with a big negative energy which is 
released in hydrolysis reaction (∆G′о ≈ −36 KJ/mol). This energy is useful for 
phosphoanhydride bonding of GTP/ATP and thus succinate can be formed. The 
reaction is catalyzed by Succinyl-CoA synthetase which gets phosphorylated (by 
the histidine residue) itself during the intermediate steps of the reaction. It has two 
subunits, α-subunit carries a phposphoryl group with a high potential for transfer, 
and β-subunit determines the specificity of the izoenzyme (GDP/ADP). The active 
point of the enzyme is located between subunits.  
ATP/GTP formation is a substrate-level phosphorylation because of energy 
saved during α-Ketoglutarate decarboxylation. If GDP is formed, it can donate its 
end phosphoryl group to ADP, so we can say the final point of every Succinyl-
CoA synthetase izoenzyme activity is ATP formation. 
 




Fig. 7a. Tricarboxylic acid cycle, step 5 
 
6) Succinate oxidation 
An enzyme succinate dehydrogenase catalyses the succinate oxidation 
reaction in which fumarate is formed. This enzyme is located on the inner 
mitochondrial membrane and contains of three FeS subunits and one FAD 
molecule (a prosthetic group).   
 
Fig. 8. Tricarboxylic acid cycle, step 6 
 
Electrons are transferred from succinate through FAD and FeS subunits. 
Electrons then get into the respiratory chain, where FAD is reducted to FADH2, 
and the acceptor role is taken by the ubuquinone. An electronic transfer through all 
these carriers to oxygen is connected with the ATP synthesis (1,5 molecule ATP 
per one electron pair).  
7) Fumarate hydration 
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Fig. 9. Tricarboxylic acid cycle, step 7 
 
 
Fig. 9a. Tricarboxylic acid cycle, step 7 
 
Fumarate is reversibly hydrated into L-Malate. During this reaction a 
carbanion (an intermediate compound of the hydration reaction) is formed. The 
enzyme engaged in this step is called fumarase. It is a stereospecific enzyme 
because it catalyzes a fumarate (trans-isomeride) olefinic linkage hydration. 
Maleate (cis-isomeride) hydration is not catalyzed by the enzyme. 
8) L-Malate oxidation 
 
Fig. 10. Tricarboxylic acid cycle, step 8 
 
This reaction is catalyzed by L-Malate dehydrogenase, which is a NAD-
dependent enzyme. L-Malate is oxidized into oxaloacetate. In vitro this reaction 
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balance is displaced to the left, although in the cell oxaloacetate is constantly 
engaged in high-exergonic citrate-synthase reaction (step 1). That’s why 
cincentration of the oxaloacetate in cell is quite low, and the reaction balance of the 
last step displaces it to the right. 
All enzymes of the Krebs cycle exist within the cell as multienzyme 
systems, which provide an effective transfer of the rections compounds from one 
step to another. These systems are called metabolones. 
The cycle is regulated by substrate availability, enzyme down-regulation and 
inhibition of the end products, which provides a stable concentration of all 
compounds. For instance, all exergonic reactions can be rate-limiting; substrate 
availability depends on the cell state; NADH/NAD+ rate can inhibit or slow down 
dehydration reactions; end products also can inhibit reactions so that carbon flow is 
enough for optimal ATP and NADH concentrations. The glycolysis rate and TCA 
cycle rate are interconnected, and other biochemical reactions also regulate this 
rate in several ways. 
 
2.3. Fatty acids oxidation and carnitine cycle 
 
A hypothesis of β-oxidation was first introduced by F. Knoop in 1904. 
Modern view of fatty acids oxidation is widely based on this theory.  
For now there are known at least 25 known enzymes and specific transport 
proteins in the β-oxidation pathway. 18 of them have been associated with human 
disease (Tein I, 2013). The oxidation contains of the following: 
1)  Fatty acids activation 
Free fatty acids are non-reactive regardless the hydrocarbon chain length. 
They pass the cell membrane through specific transport proteins such as the SLC27 
family fatty acid transport protein (Stahl A, 2004). For oxidation reaction they 
need to be activated.  Activation takes place on the outer mitochondrial membrane 
and involves ATP, HS-CoA and. Mg2+. It is catalyzed by long fatty acyl-CoA 
synthase and is driven to completion by inorganic pyrophosphatase. First ATP and 
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fatty acid form acyl adenilate, a fatty acid and AMP ether; then a sulfhydryl group 
attacks acyl adenilate; the end product of the reaction is acyl-CoA. This compound 
is an active form of fatty acid and can be oxidized. 
 
Fig. 11. Fatty acids activation 
 
2) Fatty acids transport 
Acyl-CoA is not able to reach the oxidation point which is located inside the 
mitochondria, so carnitine acts as a carrier for fatty acids with a long chain and 
transports it through the inner membrane. Acyl group is transferred from S atom to 
a hydroxyl group of carnitine. The cytoplasmic enzyme catalyzing the reaction is 
palmitoyl transferase. The end product of the reaction is acylcarnitine. This 
compound can diffuse through the inner membrane of the mitochondria with the 
help of carnitine-acylcarnitine translocase. If the fatty acyl-CoA contains a short 
chain (less than 10 carbons) it can simply diffuse through the inner mitochondrial 
membrane. 
 
Fig. 12. Fatty acids transport 
After the diffusion the acyl group is transferred back to СoA in a counter 
reaction of breakage of the acyl carnitine with a HS-СoA and mitochondrial 
palmitoyl transferase engaged. 
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3) Fatty acids oxidation 
The oxidation itself contains of several consistent steps.  
A. Dehydrogenation phase 1 
In mitochondria acyl-KoA undergoes an enzymatic dehydration and loses 
two hydrogen atoms in α- and β-positions. The end product of the dehydration is a 
CoA ether of the unsaturated acid with a double bond between C2 and C3 (trans-
delta2-enoyl CoA). The enzyme catalyzing this reaction (fatty acyl CoA 
dehydrogenase) has the specificity for the length of the hydrocarbon chain. FAD is 
an electron acceptor and it is reduced to FADH2. 
 
Fig. 13. Fatty acids oxidation, dehydrogenation phase 1 
 
B. Hydration 
The trans-delta2-enoyl CoA adds a molecule of water and forms L-β-
hydroxyacyl-CoA (3-hydroxyacyl-CoA). This reaction is catalyzed by enoyl-CoA-
hydratase which is stereospecific, similar to fumarate and aconitate hydration 
reactions. 
 
Fig. 14. Fatty acids oxidation, hydration 
 
C. Dehydrogenation phase 2 
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In this step β-oxyacyl-CoA is dehydrogenated again to get β-ketoacyl-CoA. 
This reaction is catalyzed by NAD+ dependent β-hydroxyacyl CoA dehydrogenase. 
NAD acts as an electron acceptor. 
 
Fig. 15. Fatty acids oxidation, dehydrogenation phase 2 
 
D. Thiolysis 
This is a reaction of  C2 and C3 carbons of the β-ketoacyl-CoA and is a 
degradation reaction. It is catalyzed by Acetyl CoA acyl transferase. The 
intermediate compounds are the acyl-CoA which is shorter by two carbon atoms 
and a dicarbone segment (acetyl-CoA).  
 
Fig. 16. Fatty acids oxidation, thiolysis 
 
Acetyl-CoA goes into the TCA cycle for oxidation. Acyl-CoA goes further 
into the fatty acids β-oxidation cycle again and again until the tetracarbon 
compound (butyryl-CoA) is formed. Butyryl-CoA is also oxidized and 2 molecules 
of acetyl CoA are formed. So, we can see that an oxidation of the fatty acid 
containing of N carbon atoms requires N/2–1 β-oxidation cycles, and the end 
quantity of acetyl CoA is N/2. 
Approximately 990 kcal or 42% of the reaction energy is used for the ATP 
resynthesis, and the rest of it is lost as heat. So the energy yield is about 40%, 
which is close to TCA energy yield, glycolysis energy yield and oxidative 
phosphorylation energy yield. 
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2.4. Electronic transport in the respiratory chain 
 
During the pyruvate dehydrogenase reaction and Krebs cycle, substrates 
(pyruvate, isocitrate, α-ketoglutarate, succinate, malate) are being metabolized, and 
NADH and FADH2 are formed. These coenzymes take part in the mitochondrial 
respiratory chain, which involves ATP synthesis and together it is called oxidative 
phosphorylation.   
The respiratory chain is a pathway of enzymes, providing hydrogen ions and 
electron transport from the substrate to the molecular oxygen – the final hydrogen 
acceptor. Energy in these reactions releases gradually and can be accumulated as 
an ATP molecule. Enzymes of the respiratory chain are located on the inner 
mitochondrial membrane. The chain consists of five multi-enzyme complexes, two 
electron carriers, a quinone (coenzyme Q), and a small hem-containing protein 
(cytochrome c) (Kang D, Hamasaki N, 2006). 
I. NADH-ubiquinone oxidoreductase (contains seven subunits which are 
encoded by the mtDNA and at least 39 nuclear-encoded subunits of complex I). 
II. Succinate-ubiquinone oxidoreductase (composed of four subunits, all 
encoded by the nuclear genome). 
III. Ubiquinol-ferricytochrome c oxidoreductase (holds one subunit, 
cytochrome b, encoded by the mitochondrial genome and 10 subunits encoded by 
the nuclear genome). 
IV. Cytochrome c oxidase (COX) (composed of 13 subunits, three of 
which are encoded by mtDNA and the other 10 by nuclear DNA). 
V.  ATP synthase (composed of two mtDNA-encoded subunits, and at least 
13 nuclear DNA-encoded subunits) 
Coenzyme Q (a lipoidal quinone) and cytochrome c are also involved in 
mitochondrial respiration, serving as ‘electron shuttles’ between the complexes 
(Wallace DC, 1999). 
Coenzyme Q is a fat-soluble vitamin-like molecule, able to easily diffuse in 
hydrophobic phase of inner mitochondrial membrane. Its biological role is 
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electronic transport in the respiratory chain, from flavoproteins (complexes I-II) to 
cytochromes (III). 
Cytochrome c is a chromoprotein with a hem as a prosthetic group, which 
holds ferrum with variable valence (Fe3+ and Fe2+). It is water-soluble and 
located at the periphery of the inner mitochondrial membrane in hydrophilic phase. 
Its biological role is electron transport in the respiratory chain, from complex III to 
complex IV. 
All intermediate electron carriers in the respiratory chain are arranged 
according to their redox potential. In this line the electron donating capacity 
(oxidating) decreases, and the electron attaching capacity (recovering) increases. 
The largest electron donating capacity carrier is NADH, and the largest electron 
attaching capacity is a molecular oxygen. 
Electrons enter the respiratory chain in various ways. From the NADH+ 
complex I transports electrons through FMN and Fe/S-points to ubiquinone. From 
the succinate, electrons are transported to ubiquinone by complex II or by some 
other mitochondrial dehydrogenase through FADH2 or flavoprotein linked to an 
enzyme. Oxidized coenzyme Q is reduced to an aromatic ubihydroquinone, which 
transports electrons to complex III through two haems b, one Fe/S point and one 
haem c1 – to the haem-containing protein, cytochrome c. Cytochrome c transports 
electrons to complex IV, cytochrome c oxidase.  
Cytochrome c oxidase contains two cuprum-bearing points (CuA, CuB) and 
two haems (a, a3), which help with transporting electrons to the oxygen. During 
the O2 reduction a strong anion O2- takes two protons and forms molecule of water. 
The flow of electrons is connected to a proton gradient (complexes I, III, IV).  
Thus, the respiratory chain is actually a proton pump generating a membrane 
potential of about 180 mV with a negative polarity at the matrix side of the 
membrane. ATP synthase uses this potential for matrix ADP phosphorylation, and 




2.5. Oxidative phosphorylation and regulation of the ATP synthesis 
 
Protons transfer provided by complexes I, III and IV happens in a vector 
way from the matrix to the intermembranous space. During the electron transport a 
concentration of H+ in respiratory chain increases, and pH decreases. The outer 
part of the inner membrane gets +, inner part gets -, which results in a proton 
gradient with acidic pH outside. This is called proton transmembranous potential 
(∆µН+, a chemosmotic theory by P. Mitchell). In mitochondria, the ATP-synthase 
can provide reverse proton transport to the matrix. That’s why the connection of 
electron transport and ATP production is a regulating connection. 
 
Fig. 17. ATP synthesis 
All complexes are located in the inner mitochondrial membrane and they 
can form supercomplexes; electron transport is provided by cytochrome c and 
ubiquinone mainly. Ubiquinone has a nonpolar side chain and due to this chain it 
can move within the membrane. 
Cytochrome c is located on the outer side of the inner membrane. NADH 
oxidation is happening on the inner side and in the matrix, where the citrate cycle 
and β-oxidation (sources of NADH) also occur (Fig. 17).  
ATP synthesis is the fundamental reaction of the mitochondrial respiratory 
chain, in which complex V (ATP synthase) is involved. ATP is being transported 
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with an antiport mechanism (opposite to ADP) into the intermembranous space, 
and then through porins to go to the cytoplasm.  
We can see that in the respiratory chain electrons are going from NADH or 
FADH2 to O2. Released energy is used for proton gradient on an inner 
mitochondrial membrane. ATP synthesis is connected with a reverse proton flow – 
from the intermembranous space to the matrix: when H+ goes from an area with a 
high concentration to an area with a low concentration, there is an energy release, 
and this energy is used for ATP synthesis.  
Electrons given by NADH are not going directly to oxygen. They take part 
in at least 10 redox systems, most of them are interlinked prosthetic groups of 
complexes I, III, IV. The quantity of coenzymes taking part in electron transport is 
outstanding. The total energy release is divided into small packages; each package 
size depends on the redox potential difference of the transitional products. This 
division provides decreased energy loss (app. 60% energy output).  
H+-translocating ATP-synthase is composed of two parts: protons channel 
(F0) is inserted into the membrane and is composed of at least 13 subunits; and 
catalytic subunit (F1) protruding into the matrix. The head of the catalytic part is 
formed by three α-subunits and three β-subunits, holding three active points 
between them. Body of this structure is formed by polypeptides of F0-part and γ-, 
δ- and ε-subunits of the head.  
Catalytic cycle is divided into three phases; each phase takes place in each 
active point. At first, ADP is being linked with Pi, then pyrophosphate link is 
formed and finally the end product is released. Three catalytic points catalyze the 
reaction phase during every proton transport through the protein channel F0 into 
the matrix. It is supposed that the energy of the proton transport is primarily spent 
to the γ-subunit rotation, which results in some cyclic transformation of the α- and 
β-subunits. 
The biochemical process of ATP production always depends on the cell 
energy demand. This need of harmonizing ATP production and ATP consumption 
is connected with the small concentration of enzymes: every ATP/ADP molecule is 
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to be phosphorylated and dephosphorylated many times. A simple mechanism of 
ATP production/consumption is called respiratory control and based on the 
connection with processes mentioned above. If the cell does not consume ATP at 
the moment, it hardly has any ADP. In the absence of ADP no proton gradient on 
the inner membrane can be used by ATP-synthase, which leads to inhibition of the 
electron transfer in the respiratory chain, and thus NADH can’t be re-oxidize into 
NAD+. A high ratio of NADH/NAD+ slows down the citrate cycle. This 
mechanism can work in a reverse way in case of high ATP consumption rate. If 
proton gradient creation is suppressed, substrate oxidation and electron transport 
go faster than usual, and end up with a heat, not ATP. 
There are also substances functionally dividing oxidation and 
phosphorylation, the so-called ‘dissociating agents’ or ‘uncouplers’. They 
contribute to the proton transfer from the intermembranous space to the matrix 
without any ATP-synthase involved. This kind of dissociation can occur as a result 
of mechanical damage of inner membrane, or as a result of exposure to some 
substances (uncoupling proteins), which transport protons through the membrane. 
For instance, a natural dissotiating agent is thermogenin, an uncoupling protein 
found in the mitochondria of brown adipose tissue.  
The most important cycle regulation factor is NADH/NAD+ ratio. Along 
with the pyruvate dehydrogenase and oxoglutarate dehydrogenase, NADH also 
inhibits citrate synthase and isocitrate dehydrogenase. All of these enzymes (excl. 
isocitrate dehydrogenase) can also be inhibited by the end product of acetyl-CoA 




2.6. Mitochondrial DNA and proteins 
 
As mentioned above, energy production must be adjusted to the energy 
demand. This requires a bidirectional flow of information between the nuclear 
genome and the mitochondrial genome (Poyton RO, McEwen JE, 1996). 
Moreover, almost all subunits of complexes (e.g. complex II) are encoded by both 
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) (Calvo S et al, 2006). 
The 13 genes encode seven subunits of NADH-ubiquinone reductase, three 
subunits of COX (complex IV), subunits 6 and 8 of ATPsynthase (complex V), 
and apocytochrome b, which is part of ubiquinol-cytochrome c reductase (complex 





Fig. 18. Mitochondrial DNA (Wikipedia, 2017). 
The following proteins and enzymes taking part in respiratory chain and are 






MT-ND1, MT-ND2, MT-ND3, MT-ND4, 
MT-ND4L, MT-ND5, MT-ND6 
coenzyme Q – cytochrome c 
reductase /cytochrome b 
(complex III) 
MT-CYB 
cytochrome c oxidase 
(complex IV) 
MT-CO1, MT-CO2, MT-CO3 
ATP synthase MT-ATP6, MT-ATP8 
 
MtDNA is a circular double-stranded DNA molecule 16569 bps long that 
encodes 37 genes, comprising 13 proteins, 22 mitochondrial tRNAs, and 2 rRNAs 
(Zeviani M, Di Donato S, 2004). All mtDNAs are presented as multiple copies 
collected in groups or clasters. The total quantity of the mtDNA in one cell is about 
1%. mtDNA synthesis isn’t coupled with nDNA synthesis.  The inheritance of 
mtDNA is almost exclusively maternal, although some exceptions (a few sperm 
mitochondria entering the egg) have been reported (Schwartz M, Vissing J, 2003). 
Most of the information is encoded in the heavy (purine-rich) strand (two rRNAs, 
14 tRNAs and 12 polypeptides) (Alexeyev MF et al, 2004). Both strands have no 
introns (Anderson  S et al, 1981). mtDNA has a small region called displacement-
loop (D-loop) which is non-coding and contains some promoters for two strand 
transcription (Zeviani M, Di Donato S, 2004).  
Human mtDNA contains protein-encoding and protein synthesis genes. Two 
novel transcriptional factors (TFB1M and TFB2M) cooperate with mitochondrial 
RNA polymerase and mitochondrial transcription factor A to carry out basal 
transcription of mammalian mtDNA (Falkenberg M et al, 2002). 
Replication of mtDNA continues throughout the lifespan of an organism in 
both proliferating and post-mitotic cells. It was believed that replication proceeds 
bidirectionally, asynchronously andasymmetrically, initiated at two spatially and 
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temporally distinct origins of replication, OH and OL, for the heavy and light 
strand origins of replication respectively (Clayton model) (Taanman JW, 1999). In 
recent decades an experimental evidence supporting the existence of conventional, 
strand-coupled replication of mammalian mtDNA has come out (Holt IJ et al, 
2000; Yang MY et al, 2002). 
As mtDNA is essential for the aerobic ATP synthesis system, alterations 
cause various effects on the respiratory chain itself and on the cells.  
The mitochondrial genotype is composed of a single mtDNA species 
(homoplasmy). Recently it has been found that wild-type (normal) and mutated 
mtDNA may coexist in the same cell (so-called heteroplasmy) (Wallace DC, 
1992). Due to mitochondrial polyploidy, the two mtDNA species are stochastically 
distributed to daughter cells during mitosis (Jenuth JP et al, 1996), which can 
contribute to mutation loads observed in different generations of families carrying 
heteroplasmic mtDNA. This results in a wide variety of phenotypes and diseases 
caused by mitochondrial pathology. 
Phenotypic expression of this pathology depends on the threshold effect: at 
some point the accumulated quantity of mutated gene copies are no longer 
balanced by the wild-type mtDNA, a cellular dysfunction that expresses 
phenotypically (Thorburn DR, Dahl HH, 2001).  
Despite the fact that human mtDNA is fully deciphered and many mutations 
had been discovered, the molecular mechanisms for maintenance and clinical 
presentation of mtDNA changes are much less elucidated (Zeviani M, Carelli V, 
2003; Uehara N et al, 2014). There is an evidence that these clinical presentations 
are influenced by a diverse range of factors, i.e. the mutation itself, its point and 
pathogenicity, and the affected organ energy demands. Thus, the most sensitive 
organs to mitochondrial pathology are nervous system, muscles, liver, kidney and 
heart.  
It is known that mitochondria contains >1500 different proteins in mammals 
and >1000 different proteins in yeast (Sickmann A et al, 2003; Sickmann, J et al, 
2003; Reinders J et al, 2006; Pagliarini DJ et al, 2008).  
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Mitochondria have all the needments for protein synthesis, including 
ribosomes, tRNA and mRNA. But as the 13 proteins synthesized in mitochondria 
are mostly insoluble, they substantially form the subunits of respiratory chain 
complexes and the F1Fo-ATPase synthase. Nearly all soluble mitochondrial 
proteins are coded in the nucleus and synthesized in cytoplasmic ribisomes, and are 
then transported into mitochondria (Fox TD, 2012). Some proteins including 
electron carriers, mitochondrial translocase, components of proteins transport in 
mitochondria and specific factors necessary for transcription, translation and 
replication of mDNA are synthesized this way.  
 
 
Fig. 19. Classification of identified mitochondrial proteins according to 
function (Schmidt O et al, 2010). 
 
These proteins have signal peptides on their ends ranging in size from 12 to 
80 aminoacid residues. Peptides form amphiphilic curls and provide a special 
contact of proteins and binding domains of mitochondrial receptors which are 
localized on the outer membrane. Proteins are transported to the outer membrane in 
a partially unfolded state connected to chaperones (i.e., hsp70). After being 
transported through the outer and inner membrane, the protein binds to a new 
chaperone of mitochondrial origin, which picks up the protein, is drawn into the 
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mitochondria and controls the folding process of the polypeptide chain. Most 
chaperones have ATPase activity, so that mitochondrial proteins are transported 
into mitochondria and the formation of their functionally active forms are energy-
dependent (Neupert W, Herrmann JM et al, 2007; Schmidt O et al, 2010). 
Mitochondrial ribosomes are of smaller size than 80S cytoplasmic 
ribosomes, and the initiating aminoacid for mitochondrial protein synthesis is not a 
free methionine like in cytoplasm but a bonded methionine, like N-formyl-
methionine. This suggests that mitochondrial protein synthesis mechanism is close 
to a prokaryotic one. 
 
2.7. Reactive oxygen species, apoptosis and mitochondrial theory of 
aging 
 
One of the causes for the mutations is that mtDNA is more vulnerable to 
various factors than nuclear DNA. For instance, about 95% of the all oxygen 
consumption in mitocnondria is reducted to water during the oxidative 
phosphorylation. The obligatory stage of this phosphorylation is a formation of two 
OH-groups with the participation of the cytochrome c oxidase. The remaining 5% 
of oxygen undergoes various reactions (mostly enzymatic) and becomes a reactive 
oxygen species (ROS), an unevitable byproducts of the oxidative phosphorylation.  
ROS include oxygen ions, free radicals and peroxides both of organic and 
non-organic origin. Free radicals are molecules of a small or medium size with an 
outstanding reactivity due to a presence of the unpaired electron on the outer 
electron level (Turrens JF, 2003). As we said previously, ROS are constantly 
formed in the cell as byproducts of normal oxygen metabolism. Some of them can 
appear after an ionizing radiation exposure. 
ROS carry various functions including mediation of some important 
intercellular processes, immune system induction, ionic transport mobilization and 
contribution to the programmed cell death (apoptosis). An increased ROS 
production leads to the so-known oxidative stress. 
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Oxidative stress is a balance disruption between the free radicals production 
and the mechanisms of antioxidant control in the cell. This disruption is 
accompanied by the increased free radicals formation and the antioxidant system 
failure, which leads to the cell death (Richter C., 1998; Orrenius S et al, 2006). The 
main cause of the oxidative stress is not considered to be ROS production itself but 
rather the imbalance between their generation and removal. 
Standard inhibitory analysis has shown that the generation of ROS is 
basically located within complexes I and III. Studies revealed that ROS-generating 
center must be located between flavine and rotenone-binding site, and that there 
can be more than one ROS-generating domain (Herrero A, Baria G, 2000). Within 
complex I a flavine or its union with NAD can be ROS-generating and this releases 
ROS into matrix; within complex III it is considered that ROS-generating is an 
unstable compound of semiquinone (Ku HH et al, 1993) and this releases ROS to 
both sides of the inner membrane. 
There are a few antioxidant protection systems in the mitochondria:  
1) enzymes – glutathione peroxidase, superoxide dismutase, cytochrome c, 
coenzyme Q;  
2) natural antioxidants in food – ascorbate, alpha-tocopherol, rutin, 
cerupoplasmin, etc.;  
3) low-molecular antioxidants which are synthesized in the organism itself – 
glutathione, uric acid, melatonin, lipoic acid, etc. 
During the last few decades, there has been a large amount of research data 
proving the role of mitochondria in the intracellular signal pathways leading to 
apoptosis (Zoratti M, Szabo J, 1995; Skulachev VP, 2000). There are several 
interrelated pathways for this.  
There are several mitochondrial proteins located in the intermembranous 
space such as caspase activators, cytochrome c, AIF, endonuclease G, etc. After 
they are released into the cytoplasm, they launch apoptosis and induce the cell 
death (Liu X et al, 1996; DU C et al, 2000). For instance, cytochrome c is one of 
the key elements of the respiratory chain in mitochondria and at the same time, it is 
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one of the most important proteins in the mitochondrial apoptosis pathway. 
Normally it is held in mitochondria by cardiolipine. After the free-radical oxidation 
in mitochondria is activated, acardiolipine is also oxidized, cytochrome c is freed 
and can move to the cytoplasm. There it formes a complex with apoptosis 
activation factor Apaf-1 and procaspase 9 (apoptosome), which causes a caspase 
activation downstream and launches the apoptotic cell death (Susin SA et al, 1999; 
Diehl NL, 2000). 
Increased ROS production in mitochondria and lack of antioxidants can lead 
to the damage of the electron transport chain and to a decrease of both ATP 
synthesis and activity of the ATP-dependent enzymes, including Na, K-ATPase, 
which is responsible for the cell membrane potential maintenance. As a result, a 
depolarization of the cell membrane occurs and ions flow intensivity through 
membrane increases; Ca2+ massively enters mitochondria, triggering a cascade of 
intracellular catabolic reactions (Aronis A et al, 2003). Because of the lack of ATP, 
the capacities of Ca-pump are also broken and Ca2+ cannot be removed from the 
cell (Ichas F et al, 1997; Boudreault F, Grygorczyk R, 2004). Intracellular Ca2+ 
accumulation uncouples oxidative phosphorylation and leads to a swelling of the 
mitochondria. ROS and Ca2+ leads to phospholipases activation, which cleave 
fatty acids from phospholipids.  
Fatty acids also contribute to the oxidative phosphorylation uncoupling and 
the mitochondria swelling with a change in membrane permeability known as the 
mitochondrial permeability transition (MPT) (Marchetti P et al, 1996). As MPT 
allows the entrance of the substances with molecular weight <1,5kDa, it allows the 
nucleotides to leave the matrix (Crompton M, 1999). When that happens, NAD-
dependent substrates breathing is inhibited and the mitochondria start swelling. We 
can see that MPT is enhanced by a variety of conditions, causing the elimination of 
the proton electrochemical potential and the membrane potential decrease, which is 
often used as a cell death indicator (Vercesi J et al, 2007). 
In 1972 Denham Harman, the author of the free radical theory of aging 
(FRTA), modified the theory into a mitochondrial one. It was known that there is a 
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chemical mechanism for ROS production in the mitochondria and the modified 
theory proposed that ROS cause damage to proteins, other molecules and mtDNA, 
because it is not as well protected as nuclear DNA. This in turn causes mutations 
and increases ROS production in mitochondria so that free radicals are 
accumulated in the cell, which in the long-term leads to the deterioration of cells 
and organs in the entire body (Harman D, 1972; Harman D, 1983). 
The theory has been widely debated (Poovathingal SK et al, 2009) and there 
were several hypotheses suggesting how can ROS induce mtDNA mutations 
(Conte D et al, 1996; Perez VI et al, 2009; Afanas'ev I, 2010). There were also 
some contra arguments to the association between ROS damage and aging (Yee S 
et al, 2014), suggesting that this evidence of this association is not cause-and-
effect, but may only be an indicator of some changes in the existing signal 
transduction pathways as a part of a cellular response to the aging process. 
 
2.8. Mitochondrial pathology and mitochondrial disease 
 
Mitochondrial diseases are a heterogeneous group of maladies associated 
with various disorders in the functioning of mitochondria which lead to energy 
metabolism violation. They can be caused by mutations in either mtDNA or 
nuclear genes (Koopman WI et al, 2012) or by structural or biochemical defects of 
mitochondria, resulting in a disruption of various units of the Krebs cycle, 
respiratory chain, beta-oxidation processes, etc.  
There are two main groups of these diseases:  
- a group of well-known mitochondrial syndromes, caused by mutations 
(Leber hereditary optic neuropathy (LHON), Leigh syndrome (LS), myoclonic 
epilepsy with ragged-red fibers (MERRF) syndrome, mitochondrial 
encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS) syndrome, 
neuropathy, ataxia, and retinitis pigmentosa (NAPR) syndrome, Kearns-Sayre 
syndrome, Pearson syndrome, etc.);  
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- a group of diseases or syndromes which include mitochondrial pathology 
as an important pathogenetic element (Poulton J, Tumbull DM, 2000) (diseases of 
the connective tissue, chronic fatigue syndrome, cardiomyopathy, migraine, liver 
failure, pancytopenia, different genetic disorders, including ethylmalonic aciduria 
(Rimoldi M et al, 2009), Friedreich ataxia (Rötig A et al, 1997), hereditary spastic 
paraplegia (Zeviani M et al, 1998), and Wilson disease (Lutsenko S, Cooper MJ, 
1998)). These are not strictly mitochondrial diseases. 
The concept of ‘mitochondrial disease’ was first postulated in the twentieth 
century, after several studies of the normal mitochondrial structure and function 
and the development of dye and staining techniques were published. In 1959-62 
Luft et al. studied the enzymic activities of human skeletal muscle mitochondria, 
and found an association of metabolic dysfunction with a defect in the maintenance 
of mitochondrial respiratory control and loose coupling between respiration and 
phosphorylation of ADP (Ernster L et al, 1959; Luft R et al, 1962). Later only one 
more patient with this pathology was described (Luft R, 1992). In 1964 Shy and 
Gonatas described ultrastructural changes in muscle mitochondria in children with 
myopathies (Shy GM, Gonatas NK, 1964). In 1958-68 Drachman, Kearns and 
Sayre described a syndrome of chronic progressive external ophtalmoplegia 
(CPEO) accompanied by mitochondrial changes (Kearns TP, Sayre GP, 1958; 
Drachman DB, 1968). In 1972 Olson used a modified three-color stain for muscle 
fibers of patients with CPEO and found several with an abnormally increased 
number of mitochondria of an unusual shape with crystalloid inclusions (the so-
called ‘ragged-red’ fibers) (Olson et al, 1972; Engel WK, Cinningham GG, 1963). 
Later it was evident that all these syndromes varied widely and included many 
signs and symptoms (Shapira et al, 1977).  
In 1970s-1980s, two research groups (DiMauro group, Columbia University; 
Morgan-Hughes group, UK) independently identified defects of different units in 
the respiratory chain (cytochrome c oxidase deficiency) which provided new 
knowledge about the mitochondrial pathology (Byrne E et al, 1985). Various 
mitochondrial enzyme deficiencies were described (Blass JP et al, 1970; DiMauro 
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S, DiMauro PM, 1973; Engel AG, Angelini C, 1973) and the first classification of 
the mitochondrial disorders appeared (substrate transport defects into the 
mitochondrial matrix; substrate utilization defect in the mitochondrial matrix; 
Kreb’s cycle defects; electron transport system (ETS) defects; 
oxidation/phosphorylation coupling defects) (Lombes A1 et al, 1989). 
Modern laboratory techniques allowed researchers to know more about the 
disease allowing, for instance, protein levels to be determined with the use of 
special antibodies for respiratory chain complexes, etc. In some cases a general 
suppression of all units can be detected, but sometimes only a few subunits of 
deficiency are discovered. The cause of this variability remained unclear until 1963 
when Nass and Nass had discovered a mammalian mitochondrial DNA (a full 
primary structure of human mtDNA was published in 1981 by Anderson) 
(Anderson et al, 1981) and described the phenomenon of heteroplasmy. In the 
following decade there was a breakthrough in mitochondrial pathology studies: 
Egger and Wilson postulated mitochondrial genetic inheritance (Egger J, Wilson J, 
1983; Hutchison CA, 1974); the mitochondrial genome and its abnormalities had 
been recognized; a specific point mutation of mtDNA in LHON (Shuster RC et al, 
1988) and large-scale deletions in muscle mtDNA in patients with myopathies 
(Holt IJ et al, 1988) were found; mtDNA deletions were associated with the 
phenotype of CPEO (Moraes CT et al, 1989) and genotype-phenotype correlation 
of many syndromes followed. 
We already know that during the division process of the mitochondria DNA 
copies are randomly distributed among their offspring and each cell contains 
thousands of copies. They can be all identical (homoplasmy) or they can be mixed, 
mutated copies with normal ones (heteroplasmy). If only one DNA molecule 
contains a mutated fragment, during this random distribution they can accumulate 
in different mitochondria (Wonnapinij P et al, 2008). When a certain amount of 
mitochondria in many cells of the tissue get these mutated copies, talk of 
mitochondrial disease (a threshold effect) begins (Schon EA et al, 1997). 
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As the distribution of mutated DNA in different organs and tissues differs, 
two patients with the same mutation can have different organs affected; a level of 
function impairment can also differ and change within years. In general, 
mitochondrial diseases affect organs and tissues with the highest energy demand 
most: muscles, brain, nervous tissue, etc. (Finsterer J, 2007) 
As stated previously, mtDNA mutates approximately 17 times more often 
than nDNA (Wallace DC et al, 1987) due to many different reasons, meaning that 
mitochondrial diseases can appear ‘de novo’ (Thorburn DR, 2004). Sometimes 
mtDNA mutation rate increases because of nuclear genes mutations encoding 
enzymes that control mtDNA replication. 
The way from the mutation to the clinical symptom of the disease is still not 
clearly understood. There are several hypotheses on this: mutations lead to the 
ROS accumulation, Ca2+ metabolism change and MPT activation, which cause 
apoptosis in summary (this scenario is probably more common for the 
neurodegenerative diseases) (Abramov A.Y. et al, 2010; Turnbull HE et al, 2010).  
The classification of the mitochondrial diseases is challenging because a 
purely clinical classification can not be applied, as many individuals do not fall 
into a specific category. Moreover, there is a poor correlation between phenotype 
and genotype: several individuals with the same clinical features can have different 
genetic variants (mtDNA mutation, mtDNA deletion, nuclear gene mutation etc.); 
and in addition, the research is still ongoing with changes being made all the time 
(Mancuso M et al, 2015). The only applicable classification is based on the 
molecular genetic basis of mitochondrial disease and consists of two groups: 
mtDNA mutations and nuclear DNA mutations. It is also arguable that the 
pathogenic allelic variant in a significant number of affected patients is not 
identified; moreover, there is still no comprehensive list of all genes known to 
impair mitochondrial function.  
A classification of mtDNA mutations is based on the mutated domain of the 
mtDNA and consists of the three groups: 
- Mutations of the structural genes. 
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These mutations alter a nucleotide sequence of the structural mtDNA genes. 
There are several subgroups of syndromes depending on the oxidative 
phosphorylation (OXPHOS) complex involved. 
1) Complex I genes mutations group is the largest group (LS, Leber 
syndrome, etc.) (Rotig A, 2010). 
2) Complex III genes mutations group consists of over 30 mutations so far, 
which cause myopathy as a rule (Wong LJ, 2007). They are associated 
with encephalopathy, cardiomyopathy, tubulopathy and LHON (Johns 
DR, Neufeld MJ, 1991; Valnot I. et al, 1999; Abu-Amero KK, Bosley 
TM, 2006) 
3) Complex IV genes mutations group is a large group of mutations, which 
is mostly associated with neuromuscular syndromes (Facts about genetics 
and neuromuscular diseases. Genetic and neuromuscular diseases, MDA, 
2011). 
4) The Complex V genes mutations group consists of several mutations 
associated with different symptoms, for instance, maternally inherited 
diabetes and deafness  (MIDD) (Desnuelle C et al, 2000). 
- Mutations of the rRNA and tRNA genes. 
Some mutations in the ribosome RNA and transport RNA that take part in 
mitochondrial protein synthesis can cause mitochondrial syndromes. 
Approximately 2/3 of the all mtDNA mutations are located in tRNA genes. For 
instance, a mutation A3243G from this group is diagnosed in 80% of MELAS 
syndrome patients, chronic progressive external ophtalmoplegia (CPEO) patients, 
Kearns–Sayre syndrome (KSS) patients, sensorineural hearing loss (SNHL) 
patients and in some MERRF syndrome patients (Silvestri G. et al, 1993; Sue CM 
et al, 1998; Finsterer J, 2007; Ma Y. et al, 2009), though it is essential to have high 
levels of heteroplasmy for the disease to appear in a clinical picture (Shoffner JM 
et al, 1990). 
- Structural changes of the large DNA segments 
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mtDNA deletions undermine many mitochondrial diseases and may play a 
key role in the aging process. There are two models of mtDNA deletions: an 
asynchronous mtDNA replication mechanism model and the double-strand 
mtDNA ruptures reparation model (Krishnan KJ et al, 2008). Most deletions are 
sporadic and are not transferred to the offspring (Chinnery PF et al, 2004). A big 
deletion of the domain 8488-13460 is known to be the most common cause of KSS 
syndrome (Maceluch JA, Niedziela M, 2006); the most common cause of CPEO is 
one or several deletions (van Goethem G et al, 2003; López-Gallardo E et al, 
2009); Pearson syndrome is also attributed to multiple mtDNA deletions (Rötig A 
et al, 1990). 
Nuclear DNA mutations also can cause mitochondrial disease because of the 
many genes encoding mitochondrial protein synthesis (Dimmer KS, Rapaport D, 
2008). Mitochondrial dysfunctions associated with these gene mutations are 
studied to a lesser extent. In 1989 Moraes showed dominant inheritance of multiple 
mtDNA deletions (Moraes CT et al, 1989)). In 1995 Bourgeron described a 
mutation of the flavoprotein subunit of the complex II (nucleus encoded) 
(Bourgeron T et al, 1995). In 1995 Suomalainen showed linkage to the 
chromosome 10q in autosomal dominant CPEO pedigrees with multiple mtDNA 
deletions (Suomalainen A et al, 1995). In 1996 Kaukonen showed that patients 
with autosomal dominant progressive external ophthalmoplegia had multiple 
deletions of mtDNA and a mild deficiency of one or more respiratory-chain 
enzymes carrying mtDNA-encoded subunits (Kaukonen JA et al, 1996). 
Nuclear DNA defects are more highly variable than mtDNA defects. The 
mutations of the genes can affect the oxidative phosphorylation system, protein 
synthesis, protein transport system, mitochondria movement and division, mtDNA 
transcription and replication and different enzymatic cycles and pathways in 
mitochondria (Zhu X et al, 2009). Symptoms of the mitochondrial diseases may 
vary considerably and this variety is mediated by threshold effect (Kmiec B et al, 
2006), heteroplasmy (Gilkerson RW, 2009) and the bottle-neck effect (Lightowlers 
R.N et al, 1997; Shoubridge EA, Wai T, 2007). 
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A classification of nuclear DNA mutations associated with mitochondrial 
diseases is also based on the mutated domain and consists of several groups: 
1. Mutations causing disorders of the mitochondrial respiratory chain  
A. Mutated genes encoding structural subunits (LS with complex I  
deficiency, leukodystrophy with complex II deficiency, etc.) 
B. Mutated genes encoding assembly factors (LS, hepatopathy and 
ketoacidosis, etc.) 
C. Mutated genes encoding translation factors (lactic acidosis, 
developmental failure, and dysmorphism; leukodystrophy and 
polymicrogyria, etc.) 
2. Disorders associated with multiple mtDNA deletions or mtDNA 
depletion (autosomal progressive external ophthalmoplegia, 
mitochondrial neurogastrointestinal encephalomyopathy, Alpers-
Huttenlocher syndrome, etc.) 
3. Other disorders (Coenzyme Q10 deficiency, Barth syndrome, 
mitochondrial phosphate carrier deficiency) (Chinnery PF, 2000). 
It can be assumed that the number of the syndromes of this group should be 
much higher as genes encoding 98% of mitochondrial proteins are located in the 
nucleus (Scarpulla RC, 2006). Elucidation of the molecular basis for these 
disorders is limited because only half of the estimated 1,500 mitochondrial proteins 
have been identified. 
We can see that a leading role of mtDNA mutations or nuclear genes 
mutations responsible for mitochondrial protein synthesis in many diseases has 
become evident. The number of known syndromes is increasing year by year. It 
was believed before that the cumulative incidence of all hereditary diseases 
associated with mitochondrial pathology is 1:5000 – 1:8000 in the total population 
(Chinnery PF, 2000), but some later studies proposed that at least one in 200 
healthy humans harbors a pathogenic mutation can potentially cause a 
mitochondrial disease in the offspring (Elliott et al, 2008).  
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Because of the remarkable expansion of knowledge on the molecular 
characterization of human disorders associated with the energy pathways of 
mitochondria, the term ‘mitochondrial disorders’ is currently restricted to indicate 
the clinical syndromes associated with abnormalities of OXPHOS only (Calvo S et 
al, 2006). OXPHOS disorders can be regarded as the most common group of 
inborn errors of metabolism and perhaps the most challenging to diagnose and 
manage because of their clinical and genetic variability. Initial symptoms are often 
nonspecic as respiratory-chain deficiency can theoretically give rise to any 
symptom, in any organ or tissue, at any age and with any mode of inheritance 
(Munnich A et al, 1996). A family history suggesting maternal inheritance is not 
common for children with OXPHOS disorders caused by mtDNA mutations; many 
of them have de novo mutations and many are likely to have nuclear-encoded 
disorders (Thorburn DR, 2004).  
Establishing the diagnosis of a mitochondrial disease can be difficult in 
many cases because some patients display a cluster of clinical features that fall into 
a discrete clinical syndrome (LHON, NARP, maternally inherited LS), but many 
do not. A diagnosis can be confirmed by molecular genetic testing of DNA 
extracted from a blood or muscle sample (a serial testing of single genes, a multi-
gene panel testing, and a genomic testing). A collection of the family history (3-
generation) can be useful in the detection of the inheritance mode, though many 
diseases appear as de novo mutations. There are also other methods of clinical 
investigation including plasma and/or CSF lactate concentration, ketone bodies, 
neuroimaging, cardiac evaluation, urinary organic acids, muscle biopsy, etc. They 
can be applied when the clinical picture is non-specific but there is a strong 
suspicion of the mitochondrial origin of the disorder. 
There is no effective treatment for the mitochondrial diseases so far, though 
many researchers work on this problem (Kanabus M et al, 2014). Some therapies 
are effective in animal disease models. There are also generalist (applicable to a 
wide spectrum of different disease conditions) and tailored (applicable to a single 
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condition) therapies emerging at the pre-clinical level, however, most of the 
approaches warrant more work (Zeviani M et al, 2015).  
Modern clinical practice for treatment of the various mitochondrial 
syndromes include early diagnosis and a prevention of the morbidity and mortality 
in certain conditions. Supportive pharmacological methods are being applied, 
special diets, physical exercises, surgery for some pathology, etc (Chinnery P et al, 
2006; DiMauro S, Rustin P, 2009; Finsterer J, 2010). Pharmacological treatment is 
focused on the mitochondrial functions reparation: increasing the respiratory chain 
enzymes activity, coenzymes predictors, electron carriers substitutes, antioxidants, 
etc., however not all patients respond to this treatment (Lopez LC et al, 2014; 
Nouws J et al, 2014). There are also some experimental methods based on 
interaction with the genetic system of mitochondria. Recently genetic engineering 
was employed into the clinical practice of reproductive medicine in UK, allowing 
women with mitochondrial diseases to have healthy children after their DNA was  
transplantated to the egg cell of the healthy woman with normal mitochondria (a 
three-person IVF procedure) (Knapton S, 2014). 
All these studies have made a revolution in the understanding of medical 
aspects of human energy metabolism. In addition to contributing to the theoretical 
pathology and medical taxonomy, one of the main achievements of these studies 
will be a set of effective diagnostic tools (clinical, biochemical, genetic, etc.) and 
maybe a treatment for mitochondrial pathology and mitochondrial disease. 
 
2.9. Mental disorders and mitochondrial pathology 
 
A hypothesis of a ‘lack of psychic energy as a result of the cell energy 
metabolism impairment’ in patients with mental disorders such as schizophrenia 
(SZ) was first postulated in the early 1950s (Easterday OD et al, 1952). This 
hypothesis seemed too revolutionary for the time period and did not accrue many 
followers even though further studies revealed a wide range of evidence for energy 
metabolism violation in different mental illnesses.  
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These lines of evidence can be divided into two groups. First group includes 
psychiatric signs and symptoms of mitochondrial diseases and syndromes. 
As neurons spend 40 to 60% ATP energy on maintaining the ion gradient on 
the membrane and transmitting the impulse, the OXPHOS impairment in 
mitochondrial diseases takes a key place in the clinical picture of ‘mitochondrial 
encephalomyopathy’ (Sukhorukov VS, 2008). Main neurological symptoms are 
mental retardation, seizures and stroke-like episodes. The high intensity of their 
severity often causes psychiatric symptoms to fall outside of the doctors’ attention. 
There are four main psychiatric symptoms in mitochondrial diseases: 
cognitive impairment, affective symptoms and anxiety, psychotic symptoms, 
personality disorders. Sometimes they manifest before the other classical 
symptoms of the mitochondrial disease appear and patients initiate treatment for 
psychosomatic condition (Norby S et al, 1994). The main difficulty of the 
differential diagnosis in those cases is the origin of the psychiatric symptoms: 
whether they act as the reaction to the disease (for instance, a lifetime major 
depressive disorder, MDD) or they can be assigned in the structure of the general 
mitochondrial condition. 
In 2000 Dr. Kato proposed a mitochondrial hypothesis of the mood disorders 
(Kato T, Kato N, 2000), which based on the findings that patients with BPD have 
an abnormal energy metabolism and abnormal mitochondrial DNA in the brain 
(Deicken RF et al, 1995; Kato T et al, 1997).  
The hypothesis suggests an impairment of cell metabolism associated with 
the mood disorders pathology, especially in the function of mitochondrial 
respiratory chain complexes (Rezin GT et al, 2009). Today there are several lines 
of evidence for different mitochondrial dysfunctions being an important 
component of BPD (Kato T, 2007; Kato T, 2008; Frey BN et al, 2007) and MDD 
(Erkan OM et al, 2004; Sarandol A et al, 2007). The evidence includes the results 
of magnetic resonance spectroscopy, electron microscopy, co-morbidity with 
mitochondrial diseases, the effects of psychotropics on mitochondrial functions, 
increased mtDNA deletion in the brain, and association with mtDNA 
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mutations/polymorphisms or nuclear-encoded mitochondrial genes (Jou SH et al, 
2009).  
Dr. Kato and his research team found an altered brain energy metabolism 
resembling that of CPEO (Kato T, 2005) and discovered a decrease of intracellular 
pH and phosphocreatinine in frontal and temporal lobe in non-treated and lithium-
resistant patients with BPD. This data was then confirmed by other researches. Van 
Goethem discovered a causative gene for CPEO, comorbid with depression (Van 
Goethem G et al, 2001). Siciliano reported a linkage between CPEO and BPD 
(Siciliano G et al, 2003). Konradi discovered a specific mtDNA alteration in 
postmortem brains of patients with BPD (Konradi C et al, 2004) and Dager et al 
revealed a lactate accumulation in those brains (Dager SR et al, 2004). Gardner 
detected an ATP production decrease in frontal lobe, basal ganglia and skeleton 
muscles of patients with MDD and showed a correlation between ATP production 
decrease and clinical symptoms of the disorder (Gardner A et al, 2003). Stork and 
Renshaw proposed the existence of a mitochondrial dysfunction in the pathology 
of the BPD that involves impaired OXPHOS, a resultant shift toward glycolytic 
energy production, a decrease in total energy production and/or substrate 
availability, and an altered phospholipid metabolism (Stork C, Renshaw PF, 2005). 
Second group includes mitochondria dysfunction in different mental 
disorders. 
 
2.10. Mitochondria dysfunction in mood disorders 
 
Data from multiple studies covering the mitochondria function alteration in 
mood disorders can be accumulated in the following groups: 
1) Glycolytic shift: increased lactate levels and decreased potential of 
hydrogen  (pH) 
There is data providing information of the shift away from oxidative 
phosphorylation toward glycolysis. Regarding the altered pH, it was confirmed that 
patients with BPD have an increased/decreased pH in all three states of the disease: 
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euthymic, depressed and manic state. There is evidence for the pH decrease in the 
euthymic state and in the manic or depressed state it is increased (Kato T et al, 
1998; Hamakawa H et al, 2004). 
Some of these research indicates not only a pH increase but a lactate 
elevation in the brains of the patients with BPD (Dager SR et al, 2004) and in other 
sources (Regenold WT et al, 2009). The only energy production pathway in the 
cell with altered mitochondrial function that doesn’t meet the energy demand is 
anaerobic glycolysis in which pyruvate is converted into lactate. That’s why lactate 
levels are used worldwide to confirm a diagnosis of mitochondrial disorder. 
Research suggests that decreased pH observed in previous studies may somehow 
act as a result of the increased lactate levels (Clausen T et al, 2001). 
The glutamate-glutamine cycle alteration is also known to take part in the 
pathophysiology of the glycolytic shift in bipolar disorder (Castillo M et al, 2000; 
Michael N et al, 2003; Dager SR et al, 2004) through increasing the brain cells 
energy demand (which normally elevates along with the levels of 
glutamate/glutamine). As mentioned above if the cell energy production doesn’t 
meet the current demand the only energetic pathway is to increase the glycolysis 
rate, which manifestly increases lactate levels and decreases the pH (Rudkin TM, 
Arnold DL, 1999). 
Phosphocreatine levels also appear to be altered in patients with BPD (Kato 
T et al, 1995). This compound acts as a reservoir of ATP and, in case of high 
neuronal activity, its level decreases to maintain the ATP concentration (Erecinska 
M, Silver IA, 1989; Sauter A, Rudin M, 1993). A massive and long-term decrease 
can be a sign of insufficient energy supply in the cell (Rothman DL, 1994; Kato T 
et al, 1996) and was found in a number of studies investigating the 
pathophysiology of mitochondrial diseases (Eleff SM et al, 1990; Barbioli B et al, 
1992; Barbioli B et al, 1993; Welch KM et al, 1993).  
These findings contribute to the hypotheses of a glycolytic shift in the 
pathophysiological mechanism of mood disorders. 
2) Disrupted phospholipid metabolism in the cell 
 48 
Normal cell metabolism includes cell membrane synthesis and maintenance 
which takes 10 to 15% of the verall ATP produced in the cell. Consequently when 
cell energy supply is reduced due to mitochondrial dysfunction or other reasons it 
is likely that phospholipid metabolism also gets broken. There are several studies, 
indicating this process in patients with BPD, for instance, investigating total 
choline levels (Sharma R et al, 1992), myo-inositol levels (Allison JH, Stewart 
MA, 1971; Manji HK et al, 1996; Silverstone PH et al, 2002), 
phosphoethanolamine and other phosphomonoethers levels (Kato T et al, 1993; 
Yildiz A et al, 2001) and proposing other hypotheses regarding the phospholipid 
metabolism that can potentially bring understanding to a complex pathogenetic 
mechanism of mood disorders.  
3) Oxidative stress 
As said previously, oxidative stress leads to various consequences within the 
cell, especially in mitochondria and DNA, which has now been established beyond 
reasonable doubt (Morris G, Berk M, 2015). Some of the consequences were found 
to be associated with symptom severity in mood disorders. They include decreased 
antioxidant response, increased calcium influx, lipid peroxidation, enzymes 
imbalance, nuclear DNA and mtDNA damage and others (Erkan OM et al, 2004; 
Forlenza M, Miller E, 2006; Andreazza AC et al, 2007; Machado-Vieira R et al, 
2007; Sarandol A et al, 2007; Soeiro-de-Souza MG et al, 2013; Brown MC et al, 
2014). Some of these findings were studied in further detail and were found 
responsive to mood stabilizers such as lithium and others (Machado-Vieira R et al, 
2014). 
4) Structural and morphological changes of the mitochondria 
Mitochondrial shape and intracellular distribution of mitochondria are 
believed to be closely linked to the normal energy metabolism in the cell (Escobar-
Henriques M, Langer T, 2006; Logan DC, 2006; McBride HM et al, 2006) and 
consequently any change in the size or shape or quantity of mitochondria  or 
mitochondrial reticulum in different cell types can cause diverse effects including 
normal aging and apoptosis (Bossy-Wetzel E et al, 2003), ROS production and cell 
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respiration (Picard M et al, 2013) and also some pathological events (Hermann GJ 
et al, 1998; Koopman WJ et al, 2005; Mannella CA, 2006). There are several 
mitochondrial structural abnormalities reported in patients with BPD and MDD. 
They include abnormal size, increased/decreased quantity in the cell or distribution 
within cell regions, abnormal shape, location/movement, and different changes in 
the morphology of mitochondria (Cataldo AM et al, 2010). 
5) Impairment of the OXPHOS and respiratory chain activity 
Research data confirms an impaired activity of different respiratory chain 
complexes and OXPHOS components. For instance, a decreased complex I activity 
and increased protein oxidation and nitration was found in the prefrontal cortex of 
patients with BPD (Andreazza AC et al, 2010). In animal models of mania a 
decreased activity of Krebs cycle enzymes, mitochondrial respiratory chain 
complexes, and creatine kinase in different brain structures were observed 
(Valvassori SS et al, 2010; Rezin OT et al, 2014) and all these dysfunctions were 
later reversed by mood stabilizers (Feier G et al, 2013). There are also studies 
linking OXPHOS of tubulin and actin, mitochondria movement, and synaptic 
function in bipolar disorder, suggesting that mood stabilizers may have different 
influences on OXPHOS and ETS and consequently on the direction and extent of 
mitochondrial movement (Corena-McLeod M et al, 2013). Impaired activity of 
ETS complexes of different cell types of patients with mood disorders is also 
reported by many researchers (Rezin GT et al, 2009; Gubert C et al, 2013; 
Andreazza AC et al, 2013). Vulnerability to depression in animal models is also 
linked to the impaired oxidative metabolism in mitochondria (Harro J et al, 2014). 
There are also studies suggesting alterations in levels of protein oxidation and 
nitration in dopamine-rich regions of the prefrontal cortex (Kim NK et al, 2014) 
and mitochondrial dysfunction and decreased expression of genes of the electron 
transport chain, particularly that of complex I (Andreazza AC et al, 2010; Scola G 
et al, 2012) in patients with BPD. 
6) Impaired metabolic activity in general 
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Different energy metabolism abnormalities are widespread in the brains of 
patients with mood disorders. For instance, lower metabolic rates were observed in 
different brain regions of patients with BPD and MDD (prefrontal cortex, anterior 
cingulate cortex, caudate nucleus) (Videbech P, 2000). In patients with BPD this 
rate is reported to be increased during manic episode (frontal lobe and medial 
temporal lobe, thalamus, occipital lobe) (Strakowski SM et al, 2008). There is also 
research reporting a decrease of various metabolic compounds in the brain 
involved in different processes in mitochondria as well as an altered mitochondrial 
response to stimulation in patients with SZ, BPD and MDD (Frey BN et al, 2007; 
Naydenov AV et al, 2007; Shao I et al, 2008). 
A decrease of cerebral N-acetyl-aspartate, a compound strongly connected 
with the mitochondria metabolism, was also found in the brain of patients with 
BPD. Normally N-acetyl-aspartate is present at concentrations of 8-10 mmol/l 
(Urenjak J et al, 1993) and is synthesized in mitochondria. This synthesis is energy 
dependent and stimulated by ADP (Patel TB, Clark JB, 1979). Though the exact 
function of this substance remains unclear, it is hypothesized to play an integral 
role in the energetics of neuronal mitochondria (Stork C, Renshaw PF, 2005), and 
its rates are strongly related to mitochondrial energy metabolism (Truckenmiller 
ME et al, 1985; Clark JB, 1998). Several researchers revealed a decreased N-
acetyl-aspartate levels in patients with BPD, with a correlation of illness duration 
(Winsberg ME et al, 2000; Cecil KM et al, 2002; Bertolino A et al, 2003; Deicken 
RF et al, 2003) or the effect of mood stabilizers on N-acetyl-aspartate levels. Other 
studies did not find any alteration on these levels (Ohara K et al, 1998; Hamakawa 
H et al, 1999; Castillo M et al, 2000) perhaps because of the specific treatment. 
7) Other findings 
There are several studies proposing other causes of mitochondrial pathology 
associated with mental disorders: Ca 2+ homeostasis (Dubovsky SL et al, 1992; 
Kusumi I et al, 1992; Kato T et al, 2003); dopamine and other neurotransmitters 
dysregulation (Brenner-Lavie H et al, 2009; Chen S et al, 2008); environmental 
factors (Kyle UG et al, 2006; Kroll JL, 2007) and other impacts and risk factors 
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known to affect mitochondria and/or cell respiration. There is a strong research 
trend regarding the studies for the genetic cause of mood disorders among these 
impacts. 
 
2.11. Genetic research for a mitochondrial-associated cause of mood 
disorders 
 
Searches for a genetic cause of mood disorders have yielded massive but 
inconclusive results. There is a suggestion that mitochondrial genetic variations 
and mtDNA mutations may play an important role in psychopathological 
symptoms of mood disorders, but the evidence is still limited and inconsistent 
(Anglin RE et al, 2012).  
As mentioned above, Dr. Kato and colleagues found an increased ratio of 
deletions in the postmortem brains of the patients with BPD (Kato T, Kato N, 
2000) and later reported a significantly higher rate of the 5178C mtDNA genotype 
accompanied by a lowered pH levels in similar groups of patients (Kato T et al, 
2000). In 2004 Konradi and colleagues found 'a pronounced and extensive 
decrease in the expression of genes regulating oxidative phosphorylation and the 
ATP-dependent process of proteasome degradation’ in patients with BPD (Konradi 
et al, 2004). Iwamoto and colleagues have reported a differential expression of 
mitochondria-related genes between controls and subjects with BPD (Iwamoto et 
al, 2005). Sun et al found that expression of 23 mitochondria-related genes, 
including downregulated components of the mitochondrial ETS, were altered in 
subjects with BPD (Sun X et al, 2006). Washizuka et al reported a downregulation 
of a complex I gene in lymphoblastoid cell lines (Washizuka S et al, 2009) and 
Naydenov found similar abnormalities in peripheral blood mononuclear cells of 
patients with BPD (Naydenov et al, 2007). MacDonald et al found a 
downregulation of creatine kinase mRNA levels in the hippocampus and prefrontal 
cortex of patients with BPD (MacDonald ML et al, 2006). 
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McMahon demonstrated that there is a disproportion in several mtDNA 
positions (incl. 10398A) between family members affected by maternally 
transmitted bipolar disorder and healthy ones (McMahon FJ, 2000). Kato et al 
found an increased level of mtDNA deletions in the brains of patients with BPD 
(Kato T et al, 1997; Kato T et al, 1997a) and also suggested that mtDNA 10398A 
position mutation is a risk factor for bipolar disorder (Kato T, 2001). Turecki et al 
studied families of patients with a good response to lithium treatment and found 
some locuses on different chromosomes possibly implicated in the pathogenesis of 
BPD (Turecki G et al, 2001).  
Altered mitochondrial genome expression has also been suggested, 
particularly on the gene encoding complex I (Iwamoto K et al, 2005). Later a 
mitochondrial DNA 3644 mutation was associated with bipolar disorder 
(Munakata K et al, 2004), and an accumulation of mtDNA 3243 mutation in the 
brains of bipolar patients was found (Munakata T et al, 2005). Munakata also 
discovered a linkage between the polymorphism in the mt-ND1 gene 3644T>C 
(associated with BPD) and a decreased mitochondrial membrane potential and 
complex I activity (Munakata K et al, 2004). Later 10398A>G polymorphism has 
been linked to decreased mitochondrial matrix pH, and higher baseline and post-
stimulation mitochondrial Ca2+ levels in patients with BPD and those effects  
observed mostly in patients who did not respond to lithium treatment were 
modulated by valproic acid (Kazuno AA et al, 2008). Konradi suggests that 
observed mtDNA mutations in BPD ‘might be somatic rather than inherited, 
indicating either an overall increased vulnerability of mtDNA, or a higher exposure 
to DNA-damaging factors’ (Konradi et al, 2004). 
There is also increased incidences of maternal inheritance in some mood 
disorders which can also be an indirect implication of genetic mitochondrial 
pathology involved in the pathogenesis of the disease.  
Several researchers did not find any evidence for mtDNA deletions or 
mutations taking part in the development of  BPD (Stine OC et al, 1993; Iwamoto 
K et al, 2005) or, in contrast to the previously mentioned studies, discovered the 
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increased mRNA levels of complex I genes in BPD (Ben-Shachar D, Karry R, 
2008). Other researchers discovered mutations typical for patients with BPD 
compared with healthy individuals (5178, 10398 positions in complex I zone) and 
the difference in mtDNA haplotypes between these two groups (Kirk R et al, 
1999).  
There is also data confirming not only the complex I mtDNA genes mutation 
but also nDNA (Washizuka S et al, 2003; Munakata K et al, 2004; Iwamoto K et 
al, 2005). As mentioned above, Konradi et al explored respiratory chain genes and 
found molecular-genetic pathology in both the prefrontal cortex and gyppocampus 
of the patients with BPD (Konradi C, 2004). Later this and other research found 
affected by the pH (an observed downregulation can be an artifact of sample pH 
rather than indicative of disease characteristics) (Vawter MP et al, 2006). But later 
there was a repeated data regarding the decreased expression of a cluster of genes 
in components of the mitochondrial ETS in postmortem BPD samples even with 
contriolled pH (Iwamoto K et al, 2005). 
Research on the apoptosis as the possible pathogenetic mechanism of 
affective disorders revealed an upregulation of 19 apoptotic genes (out of 44) in 
postmortem brains of patients with BPD although antioxidant genes were found to 
be markedly downregulated (Benes FM et al, 2006). Other research showed a 
significant downregulation of ubiquitin cycle genes and intracellular transport in 
patients with BPD (Ryan MM et al, 2006); an amount of shared suicide candidate 
genes in patients with MDD, BPD and SZ (Kim S et al, 2007); genes of the ETS, 
phosphatidylinositol-signalling system (Harwood AJ, 2005) and glycolysis/ 
gluconeogenesis (Sun X et al, 2006); and a global down-regulation of 
mitochondrial genes, such as those encoding respiratory chain components, in BPD 
patients (though the first result is supposed to be affected by drug treatment) 
(Bezchlibnyk YB, 2001; Iwamoto K et al, 2004). 
Symptoms of mood disorders may also be the first psychiatric manifestation 
of the MD or are somehow comorbid. Fattal reported 19 cases of mitochondrial 
diseases accompanied by different psychopathological symptoms (Fattal O et al, 
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2006). Di Mauro provided a lot of data on depression as a common symptom of the 
well-known mitochondrial disease CPEO (DiMauro S, Moraes CT, 1993). 
Siciliano suggested an association between MELAS (another mitochondrial 
disease) and BPD (Siciliano et al, 2003) and Grover reported a case of MELAS 
misdiagnosed as mania (Groover S et al, 2006). 
There are several other studies indicating that kind of comorbidity, including 
animal models (Fattal O et al, 2006; Kato T, 2006; Anglin RE et al, 2012). 
Moreover, genealogical studies have shown an increased prevalence of mood 
disorders symptoms among the maternal relatives of the patient with mitochondrial 
disease. For instance, Boles revealed a high predisposition to affective disorders in 
mothers and other relatives on maternal line of patients with mitochondrial 
diseases (Boles RG, 2005). Shoffner measured depression levels in relatives of the 
proband with mitochondrial disease on the maternal line and found an increase of 
three fold in comparison with healthy relatives (Shoffner JM, Wallace DC, 1995). 
Burnet conducted an anonymous survey in the group of patients with 
mitochondrial diseases and their family members and detected an increased 
frequency of depression symptoms in relatives on the maternal side (Burnet BB et 
al, 2005). 
This research data contributes to the hypothesis of mitochondria dysfunction 
playing a significant role in the pathogenesis of depression and bipolar disorder 
although we still can’t conclude that certain symptoms of mood disorders have a 
causal relationship with certain mitochondrial pathology. 
 
2.12. Other biological hypotheses of the bipolar disorder 
 
Current knowledge provides the background for formulation of several 
biological hypotheses of BPD based on the identification of biomarkers for 
vulnerability, disease expression and course, and treatment response. Biomarkers 
for BPD are still being researched: structural brain changes are searched for using 
neuroimaging methods; polymorphisms in a number of susceptibility genes have 
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been discovered in genetic studies; and neurochemical biomarkers are studied in 
periphery above all. (Doung A et al, 2015; Scola G, Andreazza AC, 2014) 
Neuroimaging 
Structural imaging studies in patients with BPD have identified anatomical 
and neuropathological abnormalities, which are associated with a 
neuroprogression. Moreover, previous mild traumatic brain injury has been 
identified as a risk factor for development of heterogeneous neuropsychiatric 
diseases, including BPD. (Perry DC et al, 2016)  
Disruptions to cortico–striatal–limbic circuits are the most straightforward 
method of describing the pathophysiology and symptomatology of affective 
disorders. (Mayberg HS, 2003; Savitz J, Drevets WC, 2009; Licznerski P, Duman 
RS, 2013) Morphometric measurements discover in BD patients enlargement of 
lateral and third ventricles after several manic episodes (Strakowski SM et al, 
2002)), progressive decline in hippocampal, fusiform, and cerebellar gray matter 
density after repeated episodes (Moorhead TW et al, 2007), subregion-specific 
gray matter volume reductions in the prefrontal cortex (López-Larson MP et al, 
2002), and increased rates of deep white matter hyperintensities (Kempton MJ et 
al, 2008). Neuroimaging studies have consistently demonstrated association of 
grey matter reduction in left rostral anterior cingulate cortex and right frontoinsular 
cortex thickness; that is, the most robust grey matter reductions in BPD occur in 
anterior limbic regions, which may be related to executive control and emotional 
processing abnormalities (Bora E et al, 2010). In a large study of 1710 BPD 
patients and 2594 healthy controls, the volumes of the nucleus accumbens, 
amygdala, caudate, hippocampus, globus pallidus, putamen, thalamus, and lateral 
ventricles were measured. BPD patients have been found to have volumetric 
reductions for the mean hippocampus and thalamus and enlarged lateral ventricles 
(Hibar DP et al, 2016). However, brain volume may be altered by environmental 
factors, including medication.  
Imaging data suggest that decreased activity in prefrontal cortical areas may 
result in inadequate modulation of limbic/subcortical areas, which contributes to 
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depressed mood and inadequate cognitive coping. Both regional gray-matter and 
white-matter changes appear to be present relatively early in BPD development 
(Maletic V, Raison C, 2014). Functional magnetic resonance imaging (fMRI) 
confirmed that excessive activation in brain regions associated with emotional 
regulation may contribute to the affective symptoms of BPD. Altered brain 
activation was identified in various regions in the cortico-limbic pathways; the 
most consistent findings were overactivation of the amygdala, striatum, and 
thalamus (Cerullo MA et al, 2009). All studies using fMRI in BPD supported the 
cortico-limbic hypothesis and suggest that connectivity can be more complex and 
that intra-regional disturbances should also be studied (Vargas C et al, 2013).  
Neurotransmitters  
The biological hypotheses of mood disorders are under development (Fišar 
Z, 2013). The monoamine hypothesis was initially formulated as catecholamine 
(Schildkraut JJ, 1965) and/or indolamine (Coppen A, 1967) deficiencies in the 
brain; that is, as the neurotransmitter hypothesis. Later, the monoamine hypothesis 
was revised to include the role of neurotransmitter receptors, transporters, 
catabolizing enzymes (monoamine oxidase [MAO], and COMT), and other brain 
neurobiological systems (Savitz J, Drevets WC, 2009; Heninger GR et al, 1996; 
aan het Rot M et al, 2009; Hamon M, Blier P, 2013).  
The monoamine hypothesis of mood disorder posits that an imbalance in 
monoaminergic neurotransmission in the central nervous system is causally related 
to the clinical features of depression or mania. This hypothesis has been supported 
by mechanisms of action of antidepressants (Fišar Z, 2013; Hillhouse TM, Porter 
JH, 2015; Fišar Z, 2016). Moreover, many candidate genes associated with BPD 
encode compounds influencing directly the monoamine neurotransmitter systems, 
for example, SLC6A4 (encoding serotonin transporter), TPH2, DRD4, SLC6A3 
(encoding dopamine transporter), MAO-A (encoding MAO type A, MAO-A), and 
COMT (Craddock N et al, 2001; Serretti A, Mandelli L, 2008; Rivera M, 2009).  
The advanced monoamine hypothesis46 supposes that serotonin or 
norepinephrine concentrations in the brain are regulated by MAO-A activity, and 
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that the severity of symptoms of depression is linked to changes in the activity of 
monoamine transporters in specific brain regions. The hypothesis has been 
supported by observation of elevated MAO-A density and reduced 5-HTT density 
during depressive episode. (Meyer JH et al, 2006; Meyer JH et al, 2009; Selvaraj S 
et al, 2011)  
Hyperdopaminergic function has been reported in BPD. A dopamine 
hypothesis of BPD was formulated that suggests a role of increased dopaminergic 
transmission in mania and the converse in depression (Berk M et al, 2007; Dunpol 
BW, Nemeroff CB, 2007). The hypothesis is supported by the fact that altered 
availability of dopamine transporter has been accepted as a biomarker for BD 
(Anand A et al, 2011).  
Monoamine depletion studies, genetic association studies, PET studies, and 
mechanism of action of antidepressants supported an important role of disturbed 
monoamine neurotransmission in the pathophysiology of mood disorders but have 
not evidenced the primary role of monoaminergic system in development of the 
disorder. The molecular changes underlying imbalances of neurotransmission in 
BD are not agreed upon; it is hypothesized that alterations in excitatory amino acid 
transporters, 5-HTT, and dopamine transporter contribute to altered glutamatergic 
and monoaminergic function in BD patients (Rao JS et al, 2012).  
The hypothesis that the dysfunctional muscarinic acetylcholine system is 
involved in the pathophysiology of BPD has been supported by the finding that 
there is reduced muscarinic acetylcholine M2 receptor binding in subjects with 
BPD (Cannon DM et al, 2006), which could be accounted for by a reduction in M2 
receptor affinity caused by genetic variation in the gene for M2 receptor (Cannon 
DM et al, 2011).  
Glutamate and GABA systems are posited in the pathophysiology of major 
depression and BD that extends beyond monoaminergic dysfunction (Lener MS et 
al, 2016). Glutamate levels were increased in the post-mortem brains of subjects 
with BD, while the glutamate/glutamine ratio was decreased following valproate 
treatment, and GABA levels were increased after lithium treatment. The balance of 
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excitatory/inhibitory neurotransmission seems to be central to the BPD (Lan MJ et 
al, 2009). A meta-analysis confirmed that brain glutamate + glutamine levels are 
elevated in BPD patients (Gigante AD et al, 2012),  which supported an important 
role of glutamate in the pathophysiology of BD. Due to the role of glutamate in 
neurotransmission, brain energy metabolism, astrocyte function, neurotoxicity, 
neuroplasticity, and learning, the glutamate hypothesis of mood disorders is 
expected to complement and improve the prevailing monoamine hypothesis 
(Sanacora G et al, 2008; Jun C et al, 2014). The hypothesis is supported by the 
observation that antagonists of glutamate N-methyl-D-aspartate (NMDA) receptor 
produce rapid antidepressant effect (Gerhard DM et al, 2016; Machado-Vieira R et 
al, 2015). 
Neurotrophic factors 
Neurotrophic factors are growth factors that promote neuroplasticity, 
neurogenesis, survival, differentiation, and maintenance in healthy and 
regenerating brain cells. They include nerve growth factor (NGF), BDNF, 
neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), glial cell line-derived neurotrophic 
factor (GDNF), and ciliary neurotrophic factor (CNTF). They are two classes of 
neurotrophic receptors: low-affinity nerve growth factor receptor (LNGFR, p75 
neurotrophin receptor) and a family of high-affinity tropomyosin receptor kinase 
(Trk, also tyrosine receptor kinase; types TrkA, TrkB, and TrkC). Activation of 
LNGFR by neurotrophins (NGF, BDNF, NT-3, and NT-4) may induce apoptosis; 
activation of Trk receptors support cell growth and may be antiapoptotic (pro-
survival). TrkA binds NGF, TrkB binds BDNF, NT-3, and NT-4, and TrkC binds 
NT-3.  
Intracellular signaling pathways of growth factors include: (i) Ras/mitogen 
activated protein kinase (MAPK) pathway; (ii) phosphatidylinositol-4,5- 
bisphosphate 3-kinase (PI-3K)/protein kinase B (Akt)/glycogen synthase kinase 3 
(GSK-3) pathway; and (iii) phosphoinositide pathway (phospholipase Cγ 
[PLCγ]/protein kinase C [PKC]) linked to MAPK, Akt, and/or Ca2+/calmodulin-
dependent protein kinase (CaMK) (Kaplan DR, Miller FD, 2000; Jones DM et al, 
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2003; Miller FD, Kaplan DR, 2003; Skaper SD, 2008; Fišar Z, Hroudová J, 2010). 
An important intracellular regulator of apoptosis and cell survival in the 
developing, adult, and injured nerve cells is the p53 protein family (Jacobs WB et 
al, 2006). Neurotrophin signaling and vesicular transport is linked; disturbances of 
vesicular transport lead to disturbed neurotrophin signaling and to diseases of the 
nervous system (Bronfman FC et al, 2014).  
Disturbances in activities of neurotrophic factors and related impairment in 
plasticity and resilience in brain cells has been reported in BPD. Attention is paid 
to neurotrophins and other growth factors that regulate function of brain cells, such 
as BDNF, GDNF, insulin-like growth factor 1 (IGF-1), and vascular endothelial 
growth factor (VEGF). (Einat H, Manji HK, 2006; Scola G, Andreazza AC, 2015) 
Brain-derived neurotrophic factor  
Post-mortem brains of BPD patients have shown significantly decreased 
protein and mRNA levels of BDNF in the frontal cortex, which indicates that 
decreased BDNF is part of the pathophysiology of BPD (Kim HW et al, 2010). 
Several meta-analyses have shown that there may be a correlation between low 
BDNF levels and the emergence of BPD (Fernandes BS et al, 2011; Fernandes BS 
et al, 2014; Lin PY, 2009). A systematic review and meta-analysis confirmed that 
peripheral BDNF levels in BPD are consistently reduced during manic and 
depressive episodes and plasma levels of BDNF are recovered after treatment for 
acute mania, that is, the BDNF plasma or serum levels are not different in 
euthymia when compared to controls (Fernandes BS et al, 2015; Polyakova M et 
al, 2015; Fernandes BS et al, 2011).  
Thus, reduction in serum BDNF may be a potential biomarker of acute 
episodes and could differentiate patients in a manic or depressive episode from 
those in the euthymic phase. Moreover, serum BDNF may distinguish BPD from 
unipolar depression (Fernandes BS et al, 2009), may be a biomarker of MD 
progression and severity (Fernandes BS et al, 2011; Fernandes BS et al, 2015; 
Grande I et al, 2010), may discriminate initial and advanced BD episodes 
(Karamustafalioglu N, 2015), and may reflect response to treatment (Tramontina 
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JF et al, 2009; Fernandes BS et al, 2015). The role of BDNF in the 
pathophysiology of BPD has been supported by findings that BDNF mRNA is 
decreased in cingulate and temporal cortices and in the hippocampus (Thompson 
Ray M et al, 2011; Ray MT et al, 2014) and that precursor protein proBDNF 
encoded by the BDNF gene has been suggested as a biomarker of mood disorders 
(Hashimoto K, 2010).  
Note that BDNF levels in the blood could be derived from its production by 
both brain and peripheral tissues, such as skeletal muscle, liver, and the 
cardiovascular system, and BDNF in the blood is stored predominantly in platelets 
(Pláteník J et al, 2014). Nevertheless, intact BDNF in the peripheral circulation 
crosses the blood–brain barrier (BBB) by a high-capacity saturable transport 
system (Pan W et al, 1998) and blood and plasma BDNF concentrations reflect 
brain-tissue BDNF levels (Klein AB et al, 2011).  
BDNF plays a key role in the pathophysiology of stress-related mood 
disorders. Acute stress, such as partial sleep deprivation, induced a fast increase in 
BDNF serum levels, whereas long-term stress led to sleep disturbance and 
depression as well as decreased BDNF levels (Schmitt K et al, 2016). The role of 
BDNF in the pathophysiology of BD has been evidenced by elevation of serum 
and brain BDNF levels by antidepressant, mood stabilizers, and antipsychotics 
(Sen S et al, 2008; Björkholm C, Monteggia LM, 2016), including lithium 
(Rybakowski JK, 2014).  
The Val66Met polymorphism (refSNP Cluster Report: rs6265) of the BDNF 
gene is a functionally relevant SNP affecting the secretion of BDNF and is 
implicated in differences in hippocampal volumes. The hippocampal volumes were 
reduced signifi- cantly in association with the presence of the BDNF met allele and 
with BPD diagnosis (Chepenik LG et al, 2009). However, a systematic meta-
analytical review of findings on the impact of the rs6265 SNP on hippocampal 
volumes in patients with BD suggested that there is no association between this 
BDNF polymorphism and hippocampal volumes (Harrisberger F et al, 2015). 
Another meta-analysis was performed to determine the overall strength of 
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associations between BDNF genetic polymorphism Val66Met and susceptibility to 
BD. It was concluded that there is no compelling evidence to support Val66Met 
polymorphism in the BDNF gene playing an important role in the susceptibility to 
BPD (Wang Z et al, 2014). However, plasma BDNF levels were significantly 
negatively correlated with depression scores in patients with BD. It was supposed 
that plasma BDNF in BD is not affected by BDNF Val66Met gene variants, but by 
progression of the illness itself (Chen SL et al, 2014).  
Other growth factors  
There are few studies that evaluate the role of NGF in the pathophysiology 
of BPD and the results are inconsistent (Scola G, Andreazza AC, 2015). For 
example, decreased plasma NGF was reported in BPD in the manic episode 
(Barbosa IG et al, 2011), but another study stated significantly higher IGF-1 in 
patients with bipolar I disorder and no changes in NGF (Kim YK et al, 2013).  
Effects of NT-3 and NT-4 also require more research. Serum NT-3 levels in 
drug-free and medicated patients were found to be increased when compared with 
controls and serum NT-3 levels did not differ between drug-free and medicated 
patients (Fernandes BS et al, 2010). Serum concentrations of NT-4 were reported 
to be significantly higher in BD patients than in controls (Walz JC et al, 2009). At 
baseline, in bipolar depressed patients, there were no differences between 
responders and non-responders to treatment with ketamine in serum BDNF, NGF, 
NT-3, NT-4, or GDNF (Rybakowski JK et al, 2013).  
A study of GDNF in BPD revealed that different stages of the disorder and 
drug treatment can alter activity of GDNF (Scola G, Andreazza AC, 2015). Lower 
GDNF concentrations might be involved in the pathophysiology of BD and drug 
treatment increases the GDNF (Zhang X et al, 2010).  
The evidence has been provided that IGF-1 plays a role in the 
pathophysiology of BPD (Scola G, Andreazza AC, 2015). The IGF1 gene has been 
identified as a candidate gene for susceptibility to BPD (Pereira AC et al, 2011). 
Peripheral levels of IGF-1 were found to be unchanged in patients with BPD 
compared to controls (Palomino A et al, 2013); however, it seems that lithium may 
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regulate IGF-1 levels (Squassina A et al, 2013). Low expression of IGF1 has been 
suggested as a putative biomarker for lithium unresponsiveness (Milanesi E et al, 
2015).  
Plasma VEGF levels were elevated in patients with a manic episode of BD, 
which may be associated with a neuroprotective role for VEGF (Lee BH, Kim YK, 
2012). Increased expression of the VEGF gene was also found in a depressive 
episode of BD compared to healthy control subjects (Shibata T et al, 2013). 
Lithium treatment led to decrease of VEGF mRNA levels (Kikuchi K et al, 2011). 
These results indicate that VEGF may vary with the episode of the disease and 
may be associated with the pathophysiology of BPD (Scola G, Andreazza AC, 
2015).  
It was reported that some members of the neurotrophin family, such as NGF, 
NT-3, and NT-4, can cross the BBB; NGF had the fastest influx rate and NT-3 the 
slowest (Pan W et al, 1998b). CNTF is saturably transported across the BBB from 
blood to brain (Pan W et al, 1999). IGF-1 enters the CNS by a saturable transport 
system at the BBB, which functions in synchrony with IGF-binding proteins in the 
periphery to regulate the availability of IGF-1 to the CNS (Pan W et al, 2000). It 
indicates that peripheral administration of some neurotrophins could have 
therapeutic effects within the CNS. In contrast, GDNF and VEGF do not cross the 
BBB (Boado RJ, Pardridge WM, 2009); VEGF enhances angiogenesis and 
promotes BBB leakage in the ischemic brain (Zhang ZG et al, 2000).  
Neurotrophic hypothesis  
Neurotrophic, neuroplasticity, and neurogenesis hypotheses were 
formulated, supposing a key role of post-receptor and intracellular processes 
(regulating intercellular and intracellular signaling) in the development of mood 
disorders. These hypotheses emphasize the role of stress, growth factors and 
neurogenesis in the pathophysiology of BPD (Einat H, Manji HK, 2006; Duric V, 
Duman RS, 2013; Zarate CA et al, 2006; Duman RS, 2014; Duman RS et al, 1997) 
and they are supported by neurotrophic effects of various antidepressants and 
mood stabilizers. Wnt signaling pathway and GSK-3 activity have been implicated 
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in both regulating neuroplasticity and neuroprotection (Gould TD et al, 2002; 
Gould TD et al, 2006).  
The neurogenesis hypothesis of depression proposes that depression can 
arise from impaired hippocampal neurogenesis and that antidepressants stimulate 
neurogenesis. Coupling of hippocampal neurogenesis to pathophysiology of 
depression requires further research to be confirmed (Berk M et al, 2014; Santarelli 
L et al, 2003; Sapolsky RM, 2004; Gass P, Riva MA, 2007).  
Neuroprogression is an important mechanism of BPD, and neurotrophins are 
key regulators of neurogenesis and neuroplasticity (Berk M et al, 2014; Scola G, 
Andreazza AC, 2015; Pittenger C, Duman RS, 2008). The neurotrophic hypothesis 
(Einat H, Manji HK, 2006; Duman RS et al, 1997; Duman RS, 2002; Zarate CA et 
al, 2006) postulates that mood disorders, such as BPD, are associated with a lower 
activity of neurotrophic factors, such as BDNF. Vulnerability to depression can 
arise as a result of neuronal damage (e.g., after chronic stress, long-term increased 
levels of glucocorticoids, ischemia, hypoglycemia, viral infections, and action of 
neurotoxins) and therapeutic effects of antidepressants may consist in activation of 
higher expression of neurotrophin BDNF and its receptor TrkB (e.g., through 
activation signaling pathways linked to monoaminergic systems) leading to 
increased neuronal plasticity, reactivation of cortical plasticity, and resumption of 
neuronal functions (Castrén E, Rantamäki T, 2010).  
 
2.13. Mood disorders treatment and its effect on mitochondrial function 
 
The mood stabilizing effect of drugs was discovered by chance in many 
cases and so consequently the mechanism responsible for stabilizing moods is still 
not clearly understood. It is known that several of the drugs are metabolized in 
mitochondria and take part in various mitochondrial processes, pointing to why it 
is very important to study their effects on mitochondrial metabolism. Moreover, 
the research data regarding the effects of different psychotropic drugs on 
mitochondria function is also for mitochondria dysfunction involved in the 
pathogenesis of the psychiatric diseases.  
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The observed effects cover different aspects of the possible impairment. 
Most patients with mood disorders receive drug treatment with mood stabilizers, 
antidepressants and/or antipsychotics. There is data reflecting different effects of 
psychotropic drugs on mitochondria, and they are reported to normalize the 
number of mitochondria in the brain (Iniwa IM et al, 2005), reduce the oxidative 
stress (Moylan S et al, 2014), modulate the expression of the antiapoptotic genes 
(Zarate CA et al, 2006)), increase energy metabolism and decrease oxidative 
damage under specific pathological conditions such as excitotoxicity and oxidative 
stress (Nonaka S et al, 1998; Wang JF et al, 2004; Shao L et al, 2005; Cui J et al, 
2007; Machado-Vieira R et al, 2007; Khairova R et al, 2012), inhibite some 
enzymes pathologically involved in mitochondrial energy metabolic processes 
(Chen G et al, 1999; Jope RS, Roh MS, 2006) and processes themselves 
(Burkhardt C et al, 1993; Prince JA et al, 1997; Prince JA et al, 1998; Banerjee U 
et al, 2012), down- or up-regulate gene expression (Ozaki N, Chuang DM, 1997; 
Bosetti F et al, 2002; Sun X et al, 2006), inhibit mitochondrial functions and 
expression of mitochonria-related genes in the brain (Weinbach BC et al, 1986; 
Keller BJ et al, 1992; Curti C et al, 1999; Modica-Napolitano JS et al, 2003), 
modulate calcium levels (Wasserman MJ et al, 2004) and some other activities 
(Moretti AI et al, 2003) though some of the first-generation antipsychotic drugs 
might have negative effects on mitochondrial respiration (Maurer I, Moller HJ, 
1997; Sagara Y, 1998).  
Lithium is known to enhance mitochondrial function in many ways 
including increase in cell respiration rate (Quiroz JA et al, 2008), modulation of the 
apoptosis through increasing the Bcl-2 level and reduction of the levels of some 
pre-apoptotic genes (Chen G et al, 1999; Michaelis M et al, 2006); protection of 
some genes involved in the functional damage to mitochondria against the 
alteration (Bachmann RF et al, 2009) and enhancement of their expression 
(Washizuka S et al, 2003b); desensitizing brain mitochondria to calcium, 
antagonizing permeability transition, diminishing cytochrome c release 
(Shalbuyeva N et al, 2007); increasing the activity of ETS complexes I, II and III 
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(Maurer IC et al, 2009); regulation of the intracellular Ca2+ (Kazuno AA et al, 
2008), raising the expression of glutathione-S-transferase (Wang JF et al, 2004); 
increasing N-acetylaspartate (NAA) levels (Hajek T et al, 2012) etc.  
Valproate effects are the inhibition of the substrate-specific oxygen 
consumption and mitochondrial ATP synthesis (Chiu CT et al, 2013), an 
interference with mitochondrial β-oxidation (Silva MF et al, 2008), neuroprotective 
effects on different types of cells in nervous tissue (Lai JS et al, 2006), a histone 
deacetylase inhibition (Gavin DP et al, 2009) and some are also the same as 
lithium effects, although there are differences between these two drugs (Gupta A et 
al, 2012; Kostrouchova M et al, 2007; Bielecka AM, Obuchowicz E, 2008). Its 
metabolites also inhibit dihydrolipoyl dehydrogenase activity and stabilize the 
oxidative phosphorylation (Luis PB et al, 2007). 
Antipsychotic drugs of the first generation are known to affect the electronic 
transport chain (Prince JA et al, 1997a) and inhibit complex I activity or have 
neurotoxic effects (Ukai W et al, 2004) even though atypical antipsychotics do not. 
Both of the groups increase complex IV activity in different brain regions (Shao L 
et al, 2008).  Thioridazine is reported to interact with the inner membrane of 
mitochondria and show a significant antioxidant activity (Rodrigues T et al, 2002). 
Antipsychotics also have an anti-apoptotic activity, for instance, they modulate the 
antiapoptosis genes Bcl-2 and Bcl-xL expression, inhibit the release of 
proapoptotic compounds (Saldona M et al, 2007), inhibit MPT (Kowaltovski AJ et 
al, 2001) and attenuate neurotoxicity (Wei Z et al, 2003). Some research suggests 
that these effects are a part of complex effects of antipsychotic drugs on the cell 
(Dean CE, 2006). 
Evidence for the antidepressant-induced positive effects in mitochondrial 
functions is relatively low. In general, antidepressants were known to impair 
mitochondrial function and induce toxicity (Mattson MP et al, 2008; Dykens JA et 
al, 2008). Fluvoxamine is reported to alter energy metabolism by decreasing the 
activities of citrate synthase, malate dehydrogenase, and complexes I, II-III, and 
IV; and increasing the activities of complex II, succinate dehydrogenase, and 
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creatine kinase in different dose and different brain regions (Ferreira GK et al, 
2014). Goncalves showed that citalopram and escitalopram decreased the activity 
of respiratory chain complexes (Goncalves CL et al, 2012). Hwang discovered an 
indirect modulation of mitochondrial function by tricyclic antidepressants through 
a decrease in nitric oxide production (Hwang J et al, 2008). Hroudova and Fisar 
showed that amitriptyline, fluoxetine, and tianeptine might be potent partial 
inhibitors of energized mitochondrial respiration (Hroudova J, Fisar Z, 2012). 
Ferreira suggested that antidepressant-induced mitochondrial dysfunction could be 
involved in early biochemical processes leading to changes in neuroplasticity 
(Ferreira GK et al, 2014) and Abdel-Razaq suggested that ‘the weak 
antimitochondrial actions of antidepressants could provide a potentially protective 
preconditioning effect, in which antidepressant-induced mitochondrial dysfunction 
below the threshold of injury results in subsequent protection’ (Abdel-RazaqW et 
al, 2011). 
In some research reports, the effect of the so-called metabolic drugs on 
different psychiatric symptoms of mitochondrial diseases. Researchers report the 
positive effect on mutism, hallucinations, psychotic symptoms and aggressive 
behavior in patients with MELAS after coenzyme Q treatment (Suzuki T el al, 
1990; Inagaki T et al, 1997; Kiejna A et al, 2002). Another case report describes a 
positive effect of dichloroacetat (a medicine which is used to reduce the lactate 
levels) on delirium and productive symptoms in patient with MELAS (Thomeer 
EC et al, 1998). These effects of coenzyme Q and other medications treatment such 
as carnitine and nicotinic acid were observed also in patients with the diagnosed 
mental disorder only (without any mitochondrial disease) (Onishi H et al, 1997; 
Gardner A et al, 2003; Filipek PA et al, 2003). 
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3. Statement of purpose and hypotheses 
 
 
The review was focused on the data revealing multiple connections between 
different signs and symptoms of mental disorders and various mitochondrial 
pathology. We can now see that the interpretation of all these data requires careful 
attention because it is partially controversial and some effects were observed in 
certain brain regions which can possibly indicate a result of other influences and 
not necessarily indicate a direct cause-and-effect relationship. Obviously the role 
of mitochondria in the pathogenesis of mental disorders is very complicated and 
might be different in different brain regions with maximum observed effects in the 
most vulnerable domains for each disease. 
Some promising results were obtained leading to perspective studies 
addressing deeper connections between mitochondrial functions and the pathology 
of mood disorders. A complex view of the pathology of mood disorders and the 
role of mitochondria in them is crucially important to develop new diagnostic tools 
and various therapeutic strategies for this group of devastating diseases. 
Mitochondrial parameters can be also evaluated as biological markers of bipolar 
disorder, one of the mood disorders. 
Summarizing various connections between pathophysiological processes in 
bipolar disorder and mitochondrial dysfunctions, we state a purpose for the study: 
to explore how energy metabolism in mitochondria corresponds to clinical 
evaluation of psychopathological symptoms in patients with bipolar disorder.  
Hypotheses of the study:  
Hypothesis 1. There is a set of mitochondrial functional impairment indexes 
specific for the current phase of the disorder. 
Hypothesis 2. The severity of the symptoms of bipolar disorder is associated 
with the severity of the alteration of the mitochondrial function. 
Hypothesis 3. There is a difference in the levels of mitochondrial respiration 
and enzyme activity in manic state and depressive state. 
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Hypothesis 4. There is a difference in the levels of mitochondrial respiration 
and enzyme activity in patients with BPD and healthy controls in both the acute 
state and remission. 
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4. Material and methods 
 
4.1. Study design and participants 
 
37 patients with diagnosis of bipolar disorder (F31) according to ICD-10 
were recruited from acute wards of the Department of Psychiatry of the First 
Faculty of Medicine, Charles University and General University Hospital in Prague 
and repeatedly tested using different psychopathology scales and blood platelets 
analysis methods (measurement 1 – acute phase, measurement 2 – remission). The 
control group consisted of 21 healthy volunteers matched by age and gender 
tested once using blood platelets analysis methods. Demographic data was 
collected for each person.  
The included criteria were as follows:  
• all in-patients and out-patients are already treated for BPD (at least 
second current episode); 
• acute state; 
• within one week upon hospitalization;  
• diagnosis of the BPD – F31 (phase manic, depressive, remission);  
• age 18-65.  
The excluded criteria were as follows:  
• additional diagnosis of any listed in F10-F19, F20-F29, F70-F79;  
• psychoactive substance abuse;  
• organic brain damage;  
• significant cognitive impairment;  
• history of medication abuse of any kind;  
• diagnosis of cancer or any neoplastic disease within the last 3 years;  
• a diagnosed mitochondrial disorder;  
• constantly taking medicines such as coenzyme Q, L-carnitine, vitamin 
E, chloramphenicol, doxycycline, ofloxacin, ciprofloxacin, 
perofloxacin, azathioprine, cyclosporine, tacrolimus, everolimus, 
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monoclonal antibodies, amiodarone, statins, levomepromazine, 
haloperidol;  
• participation in any study involving investigational drug within the 
last 3 months. 
The study was carried out according to the principles expressed in the 
Declaration of Helsinki and the study protocol was approved by the Ethical 
Review Board of the First Faculty of Medicine and General University Hospital in 
Prague, Czech Republic. Written informed consent was obtained from all 
participants. 
 
4.2. Questionnaires and scales 
 
All patients included were screened for bipolar disorder using the mood 
disorder questionnaire (MDQ) (Hirschfeld RM et al, 2000).  
The Mood Disorder Questionnaire is a brief, self-report screening instrument 
for bipolar disorder with both good sensitivity and very good specificity which 
includes 13 questions plus items assessing clustering of symptoms and functional 
impairment. 
Severity of current depression was tested using the MADRS 
(Montgomery–Åsberg Depression Rating Scale).  
MADRS is a ten-item diagnostic questionnaire which psychiatrists use to 
measure the severity of depressive episodes in patients with mood disorders. It was 
designed in 1979 by British and Swedish researchers as an adjunct to the Hamilton 
Rating Scale for Depression to be more sensitive to the changes brought on by 
antidepressants and other forms of treatment than the Hamilton Scale. 
A higher MADRS score indicates more severe depression, and each item 
yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire 
includes questions on the following symptoms 1. Apparent sadness 2. Reported 
sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration 
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difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal 
thoughts. 
Severity of current mania was tested using the Young Scale of Mania 
(YMRS).  
YMRS is one of the most frequently utilized rating scales to assess manic 
symptoms. The scale has 11 items and is based on the patient’s subjective report of 
his or her clinical condition over the previous 48 hours. There are four items that 
are graded on a 0 to 8 scale (irritability, speech, thought content, and 
disruptive/aggressive behavior), while the remaining seven items are graded on a 0 
to 4 scale. These four items are given twice the weight of the others to compensate 
for poor cooperation from severely ill patients. The scale is generally done by a 
clinician or trained rater with expertise of manic patients and takes 15–30 minutes 
to complete. 
Severity of illness 
General severity of illness was assessed using Clinical Global Impression - 
Improvement scale (CGI-I). CGI-I is a 7-point scale that requires the clinician to 
rate the improvement of the patient's mental illness at the time of assessment, 
relative to the clinician's past experience with patients who have the same 
diagnosis. 
Psychopathology symptoms were evaluated twice during the illness (before 
treatment, in acute state, and during treatment, in remission).  
 
4.3. Laboratory methods 
 
Peripheral blood samples were taken from the antecubital vein of each 
participant between 7:00 and 8:00 am, when all subjects were nicotine- and and 
coffee-free, before their morning medications. 24 milliliters of blood were drawn 
into BD Vacutainer® blood collection tubes with anticoagulant. Platelet rich 
plasma was separated by centrifugation at 200×g for 10 min at 25 °C. Platelets 
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were counted by microscopy using a counting chamber and immediately used for 
measuring of mitochondrial parameters.  
The energy metabolism related to mitochondrial dysfunctions was analyzed 
in biochemical laboratories (First Faculty of Medicine). Selected mitochondrial 
parameters (citrate synthase and electron transport chain complexes activities, ATP 
production and mitochondrial respiratory rate) and functional changes in 
monoaminergic system (MAO activity, serotonin uptake) were measured in 
peripheral blood components. High-resolution respirometry, fluorescence, 
radiochemical and spectrophotometric methods were used. 
Complexes of ETS – complex I, II, II+III and IV and citrate synthase were 
measured spectrophotometrically (Hroudová and Fišar, 2010). The relative 
activities of mitochondrial complexes were expressed as a ratio between specific 
enzyme activities and citrate synthase serving as the control mitochondrial matrix 
enzyme. 
Mitochondrial respiration was evaluated by both respiratory rate and 
respiratory control ratios (RCRs) using high resolution respirometry using 
(oxygraph) with Clark type oxygen electrodes (Fišar et al., 2016). Respiratory rate 
was determined as time derivation of oxygen concentration in the sample and 
RCRs was calculated as ratios of respiratory rates measured before and after 
substrates and/or inhibitors of OXPHOS. 
 
4.4. Statistical methods 
 
The study materials were statistically processed using the methods of 
parametric and nonparametric analysis in accordance with the results of testing the 
compared populations for normal distribution. Accumulation, corrections and 
systematization of the initial information and results visualization were performed 
in Microsoft Office Excel 2010. The statistical analysis was performed using the 
IBM SPSS Statistics v.20 program. 
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Each of the comparable sets of quantitative data was evaluated for 
compliance with the standard normal distribution law using the Shapiro-Wilk test 
which is recommended when a number of subjects are less than 60. The data 
distribution histogram, asymmetry and kurtosis parameters were also taken into 
account. 
If a normal distribution of quantitative data was confirmed, the obtained data 
was combined into a variation series, in which the arithmetic mean values (M) and 
the standard deviations (σ) were calculated. The analysis was performed using the 
parametrical statistics method. 
If the quantitative data distribution was non normal, the obtained data was 
described using the median (Me) and the lower and upper quartiles (Q1 and Q3). 
The analysis was performed using the nonparametric statistics method. 
To assess the statistical significance of the differences in the mean values of 
normally distributed populations, the Student t-test was calculated (1): 










= ,    (1) 
where: М1 and М2 – compared averages, m1 and m2 – standard errors of the 
average values. 
When comparing the average values calculated for dependent populations 
(for example, before treatment and after treatment values), the paired Student t-test 
was calculated (2): 
      ,   (2) 
where: XD - the average, sD - standard deviation of those differences, µ0 - 
non-zero. The degree of freedom used is n − 1, where n represents the number of 
pairs. 
The obtained values of Student t-test were compared with critical values. 
Differences were considered statistically significant at a significance level of 
p<0.05. 
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To compare independent sets of quantitative data with a non normal 
distribution the Mann-Whitney U test was used. First a single ranked series from 
both of the compared samples were formed, where elements were sorted according 
to the value increase. A smaller rank was attributed to a smaller value. Then a 
single ranked series was divided into two, consisting, respectively, of the first and 
second samples units. The rank amounts were counted separately for each of the 
series. The Mann-Whitney U test was calculated (3): 






21 ,   
 (3)  
where n1 – number of elements in sample 1, n2 – number of elements in 
sample 2, nx – number of elements in the bigger sample, and Tx – ranks sum for the 
bigger sample. 
The calculated Mann-Whitney U test values were assessed by comparing 
them with the critical values: whether the calculated value was less or equal to the 
critical one, the statistical significance of the differences was accepted. 
To assess the differences between two compared pairs of samples with a non 
normal distribution the Wilcoxon W-test was used. The change value was 
calculated for each patient. All the changes were ordered according to the absolute 
value. Then the signs of change ("+" or "-") were assigned to ranks and the ranks 
were summed up for each sign. The smaller rank amount (W) was compared to the 
W test critical value: whether the calculated value was less or equal to the critical 
one, the statistical significance of the differences was accepted. 
To compare several groups of the patients (more than 2), a one-way analysis 
of variance was used. To assess the statistical significance of the differences the 
Fisher F test was calculated (4): 








    (4)
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where Q1 – sum of the sample means to overall average squared deviations, Q2 – 
sum of the observed values squared deviations, n – number of the elements, and m 
– number of the samples. 
If the calculated value of Fisher's F test was less than critical, we made the 
conclusion that there was no statistically significant effect of the studied factor on 
the mean values of the trait. If the calculated value of Fisher's F test was larger 
than critical, the significant influence of the independent factor on the mean values 
for a certain level of statistical significance was recognized.  
If statistically significant differences between groups existed, an additional 
pair comparison of the populations using the a posteriori criterion of Scheffe was 
carried out. To check the tightness of the relationship of the quantitative indicators 












    (5) 
To evaluate the quality of the linear function selection, the square of the 
linear correlation coefficient R2 (the coefficient of determination) was calculated. 
The coefficient of determination shows the percent of factors considered in the 
model. 
For the evaluation of the statistical significance of the correlation coefficient 












    (6) 
The obtained value was compared with the critical value for a certain level 
of significance and the number of degrees of freedom n-2. If the calculated value 
of tr was larger than tcrit, a certain level of statistical significance was recognized. 
The values of the correlation coefficient were interpreted in accordance with 
the Chaddock scale (Tab. 1) 
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Tab. 1. The determination of the closeness of the correlation relationships, 
Chaddock scale 
Coefficient  Quality characteristic 
<0,1 No relationships 
0,1 – 0,3 weak 
0,3 – 0,5 moderate 
0,5 – 0,7 salient 
0,7 – 0,9 high 
0,9 – 0,99 Very high 
 
To assess the dependence of one quantitative parameter to others, the linear 
regression method was used, and the reduced equation of the following kind was 
given (7): 
    y = a0 + a1x1 + … + anxn,    (7) 
where y – quantitative trait, x1…xn – factor traits, a0 – constant, a1…an–  regression 
coefficients, showing the average change in the result y with a change in the factor 
x by one unit. 
The obtained regression model allows us to calculate the theoretical values 
of the effective sign y from the given values of the factor x. 
To compare the nominal scale values Pearson χ2 test was used. It allows us 
to assess the significance of the differences between the actual number of 
outcomes or qualitative characteristics of a sample falling into each category, and 
the theoretical amount that can be expected in the study groups when a null 
hypothesis is valid. 
First, the expected number of observations in each of the cells of the 
conjugacy table was calculated, provided that the null hypothesis of the absence of 
an interrelation was valid. For this purpose, the sums of rows and columns 
(marginal totals) were multiplied with the subsequent division of the obtained 
product by the total number of observations. 














χ     (8) 
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where i – the row number (from 1 to r), j – the column number (from 1 to с) Oij – 
actual number of observations in the cell ij, and Eij – the expected number of 
observations in the cell ij.  
Then the value of the Pearson χ2 test was compared to the critical values for 
(r-1) × (c-1) number of degrees of freedom. If the obtained value was larger than 
critical, a certain level of statistical significance was recognized and a statistical 
relationship between the studied risk factor and the outcome was confirmed. 
For the four-field table analysis, when the number of expected observations 
in any of the cells of the four-field table was less than 10, the χ2 test with the Yates 
correction was calculated. It reduces the risk of the first type error, i.e., detection of 
non-existent differences. The Yeats correction includes subtracting 0.5 from the 
absolute value of the difference between the actual and expected number of 
observations in each cell, which leads to a decrease in the χ2 test value (9):. 













χ     (9) 
To estimate the significance of the differences when the number of 
expected observations in any of the cells of the four-field table was less than 5, an 





++++=    (10) 
where A, B, C, D – actual numbers of observations in the cells of the contingency 
table, N – total number of the participants, and ! – a factorial, equal to the 
multiplication of a number by a sequence of numbers, each of which is less than 
previous by 1. 
An obtained value of Fisher's exact P test more than 0.05 indicated the 
absence of statistically significant differences. An obtained value of Fisher's exact 
P test less than 0.05 indicated their presence. 
To compare the relative values characterizing the associated populations (at 
the beginning and at the end of the observation) the McNemar test was used. It is 
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used to determine whether any changes in the distribution structure values of two 
dependent variables occur (11): 






−=      (11) 
where Q – McNemar test, b – the number of patients with a negative result in the 
first observation and positive result in the second, and c – the number of patients 
with a positive result in the first observation and negative result in the second.  
The McNemar test values were interpreted by comparison with critical 
values. 
To identify factors that characterize the relationships between groups of 
characteristics and to reduce the number of analyzed variables, a four-stages factor 
analysis was used: 
1) calculation of the correlation matrix for all variables participating in the 
analysis; 
2) extraction of factors by the principal component method; 
3) the rotation of factors to create a simplified structure using Varimax 
method; 




5.1. Clinical evaluation of the BPD patients in manic or depressive 
episode  
 
All the subjects were divided into 2 groups: experimental group (37 patients 
with BPD) and control group (21 healthy individuals). The experimental group, in 
turn, consisted of 24 patients in manic episode of the disease (subgroup A) and 13 
patients in depressive episode of the disease (subgroup B). Clinical evaluation and 
biochemical measurement of BAD in-patients were done both at the beginning of 
treatment and when released from hospital treatment (in remission or partial 
remission).  The average age within groups is shown in Table 2. 
Tab. 2. Age structure in the experimental group (patients with bipolar 





- All 21 – 65 42.2±12.2 37 
- Subgroup А 21 – 65 39.5±13.2 24 
Experimental 
 
 - Subgroup B 30 – 59 46.9±8.7 13 
Control  25 – 61 40.3±10.3 21 
Subgroup A = manic episode; Subgroup B = depressive episode 
 
A one-way analysis of variance (ANOVA) did not show a statistically 
significant difference in age between control group and experimental groups (all 
p=0.565, subgroup A p=0.156, and subgroup B p=0.147); it proves that groups are 
age-matched and no correction for age is necessary in data analysis. 
First stage of the research included the assessment of the mental state of the 
patients with BPD. The following tests were used for patients in the manic episode: 
Brief Psychiatric Rating Scale (BPRS), Young Mania Rating Scale (YMRS),  
Mood Disorder Questionnaire (MDQ). Tests for patients in the depressive episode 
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included: BPRS, Montgomery-Asberg Depression Rating Scale (MADRS), MDQ. 
For patients in remission we added Clinical Global Impression – Improvement 
scale (CGI-I) to measure the clinical improvement. (Tab. 3) 
Tab. 3. Mental state assessment in the experimental group at the beginning 
of treatment and when released from treatment (measurements 1 and 2) 
 
State of the patient 





Depressive  55 (44.5-68.5) 30 (27-33) <0.001 
Manic  51.5 (41.5-66.5) 33 (29-41.5) 0.018 
BPRS 
 
p 0.952 0.177 - 
MADRS Depressive  26.5 (19-31) 4 (0-4) <0.001 
YMRS Manic  20 (13.5-26) 1.5 (0-5) <0.001 
CGI-I  - xx  
Mean (range); p – significance level 
Data obtained from the Wilcoxon-Mann-Whitney test shows that the 
difference between the BPRS test scores in the acute state of the disease and in 
remission was significant within both A (p<0.001) and B (p=0.018) subgroups. In 
patients with mania the median BPRS score decreased from 51.5 to 33 and in 
patients with depression it decreased from 55 to 30. The decrease was comparable 
in both the subgroups. The difference in BPRS test scores between patients with 
mania and patients with depression were not significant in either the acute phase of 




Fig. 20. BPRS test score in patients with mania and depression at the beginning 
and at the end of the study. Subgroup A = manic episode, Subgroup B = depressive 
episode. BPRS – Brief Psychiatric Rating Scale 
The Wilcoxon-Mann-Whitney test was also applied to establish the difference 
between the MADRS test score in the acute state of the disease and in remission.  
The decrease after treatment was significant (p<0.001). The median MADRS 




Fig. 21. MADRS test results in patients with depression at the beginning and at the 
end of the study 
 
A significant decrease in the YMRS test score between patients in the manic 
episode and patients in remission was also established (p<0.001). The median in 





Fig. 22. YMRS test results in patients with mania and depression at the 
beginning and at the end of the study 
  
 The results of the CGI-I test were examined only at the end of the research 
as it is used to assess the quality of remission in mentally ill patients. (Tab. 4) 
 
Tab. 4.  CGI-I test results in patients with bipolar disorder in manic and depressive 
episode at the end of the study (remission) 
 
Subgroups 
А (mania) B (depression) CGI test 
Me Q1-Q3 Me Q1-Q3 
p 
Scale I 2 1-2 2 1-3 0.694 
Scale II 2 1-2 2 1-2 0.885 
Scale III 41 41-42 41 31,5-41,5 0.462 
p – significance level; Me = mean range; Q1- Quartile 1, Q3 - Quartile 3. 
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 The Wilcoxon-Mann-Whitney test did not reveal a significant difference 
between the CGI-I test results in either A or B subgroups (p>0.05 for all CGI-I 
scales). Median assessments for the scales I, II, III were 2, 2, 41 respectively. We 
can summarize that there was no difference in the quality of clinical improvement 
between patients with bipolar disorder in a manic episode and patients with bipolar 
disorder in a depressive episode.  
 
5.2. Mitochondrial functions in BPD patients and healthy controls 
 
The second stage of the research consisted of the comparison of the 
mitochondrial function in patients with BPD (in acute manic or depressive 
episodes) and healthy controls.  
Activities of mitochondrial enzymes, citrate synthase (CS), complexes I 
(CI), II (CII) and IV (COX) in patients with BPD are graphically presented in Fig. 






































Fig. 23. Mitochondrial enzymes activity in the experimental group (patients 
with bipolar disorder in depressive episode, N=13). Min, Mean-SD, Mean+SD, 













































Fig. 24. Mitochondrial enzymes activity in the experimental group (patients 
with bipolar disorder in manic episode, N=24). Min, Mean-SD, Mean+SD, Max, 
where SD – standard deviation 
After the post-hoc Scheffe test was performed, significant differences were 
not found between any of mitochondrial enzymes activity in patients with mania 
and depression (Tab. 5). The mitochondrial enzymes activity data from the group 
of healthy controls was not available; reference ranges of mitochondrial enzyme 
activities were obtained from mitochondrial laboratory of the Department of 
Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University 
and General University Hospital in Prague. 
 
Tab. 5.  Mitochondrial enzymes in patients with bipolar disorder in a manic or 







CS (nmol·min-1·mg-1) 68.9±11.8 64.0±19.6 0.397 60-92 
CI (nmol·min-1·mg-1) 53.2±19.0 57.8±22.9 0.561 21-55 
CII (nmol·min-1·mg-1) 8.07±3.96 7.87±3.41 0.89 5-15 
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COX (nmol·min-1·mg-1) 19.44±5.91 15.03±5.57 0.054 16-40 
CS = citrate synthase; CI = Complex I; CII = Complex II; COX = Complex IV 
Mean ± SD; p – significance level 
 
Complex I (CI) activity in BPD patients with mania was lower than in 
patients with depression; Complex II (CII) activity in BPD patients with mania was 
higher than in patients with depression; citrate synthase (CS) activity in BPD 
patients with mania was higher than in patients with depression, though none of the 
above had reached statistical significance. When comparing a decrease in Complex 
IV (COX) activity in BPD patients with depression with BPD patients with mania, 
the significance level was close to 0.05 (Fig. 25). Complex IV activity in BPD 


































Fig. 25. Complex IV (COX) activity in patients with bipolar disorder in 
manic episode and depressive episode, p=0.054. Min, Mean-SD, Mean+SD, Max, 
where SD – standard deviation 
 
Changes in mitochondrial respiration in the blood platelets isolated from 
patients with BPD and healthy controls were examined through the general linear 
model, one-way analysis of variance and post-hoc Scheffé test. The results are 
summarized in Tab. 6. 
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Tab 6. Mitochondrial respiration in the blood platelets from patients with bipolar 






























































































































0.723 0.076±0.031 0.338 
Mean ± SD; p – significance level in reference to controls.  
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PR – physiological respiration, LEAK – nonphosphorylating respiration measured after the 
addition of oligomycin, ETSC – electron transport system capacity measured after titration with 
uncoupler (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone, FCCP), IR – initial 
respiration in washed platelets before permeabilization with digitonin, DMP – respiration 
measured after the addition of digitonin+malate+pyruvate, ADP – stage 3 respiration supported 
through Complex I measured after the addition of ADP, Glutamate – stage 3 respiration 
measured after the addition of glutamate, Succinate – state 3 respiration supported through both 
Complex I and Complex II measured after the addition of the succinate, Rotenone – respiration 
after Complex I inhibition measured after the addition of rotenone. (p) indicate permeabilized 
platelets. 
 
In intact platelets, the nonphosphorylating respiration measured after the 
addition of oligomycin (LEAK) was significantly higher in BPD patients with 
mania than in controls (p=0.005). LEAK was also higher in patients with 
depression than in controls, and higher in patients with mania than in patients with 
depression, though the difference did not reach statistical validity. Other indexes 
such as electron transport system capacity (ETSC) and respiration after inhibiting 
complex I with rotenone (Rotenone) were lower in patients in both phases of BPD 
than in healthy controls, and lower in depression than in mania, though these 
differences were not significant. Physiological respiration (PR) appeared to be 





























































Fig. 26. Mitochondrial respiration normalized for platelet concentration in 
intact platelets of patients with BPD in depressive episode. PR - physiological 
respiration, LEAK – nonphosphorylating respiration measured after the addition of oligomycin, 
ETSC – electron transport system capacity, Rot – respiration after complex I inhibition, 
































































Fig. 27. Mitochondrial respiration normalized for platelet concentration in 
intact platelets of patients with BPD in manic episode. PR - physiological respiration, 
LEAK – nonphosphorylating respiration measured after the addition of oligomycin, ETSC – 
electron transport system capacity, Rot – respiration after complex I inhibition, measured after 



























































Fig. 28. Mitochondrial respiration normalized for platelet concentration in 
intact platelets of healthy controls. PR - physiological respiration, LEAK – 
nonphosphorylating respiration measured after the addition of oligomycin, ETSC – electron 
transport system capacity, Rot – respiration after complex I inhibition, measured after the 
addition of rotenone. 
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After the normalization for CS activity, mitochondrial respiratory rate did 
not show any significant difference between the group of patients with BPD in a 
manic episode and control group or between the group of patients with BPD in a 
manic or depressive episode.   
We also measured a flux control ratio (the ratio of a respiratory rate at a 
specific respiratory state divided by ETSC); e.g. LEAK/ETSC ratio was 
significantly higher in patients with BPD in a manic episode than in healthy 
controls (p=0.03) and in patients with BPD in a depressive episode than in healthy 
controls (p=0.042) (Fig. 29, 30) 
 
 
Fig. 29. The LEAK/ETSC index (flux control ratio) in intact platelets of 




Fig. 30. The LEAK/ETSC index (flux control ratio) in intact platelets of 
patients with BPD with depression and healthy controls, p=0.042 
 
The mean LEAK/ETSC in intact platelets of patients with BPD episode  was 
slightly higher in BPD patients in both manic and depressive episodes compared to 
controls, which may indicate a disturbance in the mitochondria coupling process 
and/or functional integrity in the inner mitochondrial membrane in BPD.  
In permeabilized platelets LEAK index (nonphoshorylating respiration after 
the addition of oligomycin) was also significantly higher in BPD patients with 
mania (p=0.034) than in healthy controls. LEAK was also lower in patients with 
depression than in patients with mania, though these changes did not reach 
statistical validity (p=0.058). Other respiratory rates such as ADP, Succinate did 
not reveal a significant difference between the groups. The results are summarized 
in Table 6 and Fig. 31. 
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Fig. 31. The LEAK/ETSC index (a part of the flux control ratio) in 
permeabilized platelets of patients with BPD with mania and healthy controls, 
p=0.042 
 
A comparable analysis for the mitochondrial enzymes activity and 
mitochondrial respiration in the group of BPD patients in remission and healthy 
controls was also performed. The comparability of the indexes in subgroups A and 
B was estimated through Student t-test. The results are summarized in Tab. 7.  
  
Tab. 7. Mitochondrial respiration in the blood platelets from patients with bipolar 




































LEAK 0.00466± 0.049 
0.00356± 


























































































































Mean ± SD; p – significance level in reference to controls . PR – physiological respiration, 
LEAK – nonphosphorylating respiration measured after the addition of oligomycin, ETSC – 
electron transport system capacity measured after titration with uncoupler (carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone, FCCP), IR – initial respiration in washed platelets before 
permeabilization with digitonin, DMP –respiration measured after the addition of 
digitonin+malate+pyruvate, ADP – stage 3 respiration supported through Complex I measured 
after the addition of ADP, Glutamate – stage 3 respiration measured after the addition of 
glutamate, Succinate – state 3 respiration supported through both Complex I and Complex II 
measured after the addition of the succinate, , Rotenone – respiration after Complex I inhibition 
measured after the addition of rotenone. (p) indicate permeabilized platelets. 
 
 
In intact platelets, the LEAK was significantly higher in patients with 
bipolar disorder in remission after a manic episode (0.00466 pmol·sec-1·10-6 
platelets) than in controls (0.00169 pmol·sec-1·10-6 platelets, p<0.05) (Fig. 32). 
Other indexes such as ETSC and respiration after inhibiting complex I with 
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rotenone (Rotenone) were lower in patients with patients with bipolar disorder in 
remission after a manic episode than in healthy controls, however these differences 
were not significant. PR index was similar in both groups. After the normalization 
for CS activity, the mitochondrial respiratory rate had shown no significant 
difference between the group of patients with bipolar disorder in remission after a 
manic episode or a depressive episode and control group.  
In permeabilized platelets there was no significant difference in the 






































Fig. 32. The LEAK index in intact platelets of patients with bipolar disorder in 
remission after manic episode and healthy controls, p=0,042 
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5.3. Changes in mitochondrial function of BPD patients during the 
research period 
 
An assessment of the changes in mitochondrial enzymes activity and 
mitochondrial respiration of BPD patients during the research period was also 
performed, i.e. values in the acute phase before treatment (manic or depressive 
episode) and after treatment (in remission) were compared (Tab. 8). 
  
Tab. 8.  Activities of mitochondrial enzymes in platelets of BPD patients in acute 






Acute Remission p 
Mania 68.9±11.8 63.9±9.7 0.063 
CS, nmol·min-1·mg-1 
Depression 64.0±19.6 65.3±19.3 0.687 
Mania 53.2±19.0 59.3±27.8 0.526 
CI, nmol·min-1·mg-1 
Depression 57.8±22.9 80.2±19.3 0.352 
Mania 8.07±3.96 7.62±3.33 0.467 
CII, nmol·min-1·mg-1 
Depression 7.87±3.41 8.09±3.41 0.799 
Mania 19.44±5.91 19.39±4.29 0.985 
COX, nmol·min-1·mg-1 
Depression 15.03±5.57 15.57±5.43 0.72 
Mean ± SD; p – significance level. CS – citrate synthase, CI – Complex I, CII – Complex II, 
COX – Complex IV. 
 
The CS activity in BPD patients with mania was higher than in healthy 
controls though the difference did not reach statistical validity (p=0,063). The 
difference between other enzymes activity such as CI, CII and COX for the groups 
of BPD patients and healthy controls also did not reach statistical validity. The 




Fig. 33. Activities of mitochondrial enzymes in patients with BPD in an 
acute phase of the disease (manic or depressive episode) compared with remission 
 
We have also compared the mitochondrial enzymes activity and respiration 
rates in the subgroups A and B: patients with mania vs patients with depression. 
The results obtained through paired test calculation are summarized in Tab. 9. 
 
Tab. 9. Mitochondrial respiration in blood platelets from patients with bipolar 
disorder in manic or depressive episodes before and after treatment 
 Disease state 




Acute Remission p 
Mania 0.105±0.017 0.106±0.033 0.885 
PR 
Depression 0.101±0.014 0.106±0.022 0.538 
Mania 0.00656±0.00483 0.00548±0.00121 0.431 
LEAK 
Depression 0.00534±0.00241 0.00301±0.00095 0.079 
Mania 0.124±0.022 0.129±0.044 0.604 
ETSC 























Mania 0.087±0.021 0.083±0.028 0.349 
IR (p) 
Depression 0.082±0.026 0.088±0.029 0.629 
Mania 0.046±0.028 0.038±0.014 0.215 
DMP (p) 
Depression 0.034±0.014 0.036±0.012 0.555 
Mania 0.108±0.031 0.107±0.049 0.964 
ADP (p) 
Depression 0.097±0.032 0.108±0.029 0.547 
Mania 0.115±0.036 0.114±0.055 0.925 
Glutamate (p) 
Depression 0.107±0.044 0.125±0.039 0.478 
Mania 0.183±0.042 0.186±0.072 0.945 
Succinate (p) 
Depression 0.166±0.059 0.192±0.055 0.429 
Mania 0.03042±0.00825 0.02939±0.01298 0.552 
LEAK (p) 
Depression 0.02643±0.0104 0.02647±0.00858 0.66 
Mania 0.177±0.054 0.183±0.082 0.775 
ETSC (p) 
Depression 0.162±0.056 0.186±0.049 0.49 























Depression 0.075±0.025 0.089±0.039 0.448 
Mean ± SD; significance level. PR – physiological respiration, LEAK – nonphosphorylating 
respiration measured after the addition of oligomycin, ETSC – electron transport system 
capacity measured after titration with uncoupler (carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone, FCCP), IR – initial respiration in washed platelets before 
permeabilization with digitonin, DMP –respiration measured after the addition of 
digitonin+malate+pyruvate, ADP – stage 3 respiration supported through Complex I measured 
after the addition of ADP, Glutamate – stage 3 respiration measured after the addition of 
glutamate, Succinate – state 3 respiration supported through both Complex I and Complex II 
measured after the addition of the succinate, Rotenone – respiration after Complex I inhibition 
measured after the addition of rotenone. (p) indicate permeabilized platelets. 
  
There were no significant differences between an acute stage of illness and 
remission in BPD patients (p>0.05 for all the measurements). 
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5.4. Connections between mitochondrial function and psychopatholo-
gical symptoms in BPD patients 
 
We also calculated correlation coefficients between the BPRS, YMRS, 
MADRS, MDQ and CGI-I tests and mitochondrial complexes activity to establish 
the association between the state of the disease, psychopathological symptoms, 
clinical improvement and mitochondrial pathology. A significant correlation was 
observed between Complex I and the BPRS score in the subgroup A (patients with 
mania, acute state – measurement 1) (p=0.001). The Pearson coefficient showed a 
high closeness of relationships according to Chaddock scale (rxy = 0.747), which is 
the evidence of the correlation validity. The paired linear regression equation 
shows the Complex I value dependence of BPRS score (1): 
BPRS = 18.66 + 0.7*CI    (1) 
where BPRS – Brief Psychiatric Rating Scale, mental state assessment scale in 
patients with BPD, manic episode, acute state (points), CI – Complex I activity 
(nmol·min-1·mg-1).  
 Based on the regression coefficient value, with the CI increase of 1 
nmol·min-1·mg-1 we expect a BPRS score increase of 0.7 points. The coefficient of 
determination R2 was 0.558 which indicates that 55.8% factors are taken into 
account in the regression model (1).  




Fig. 34. Linear dependence diagram for the mental state of BPD patients with 
mania and Complex I activity  
 
There were no significant correlation coefficients between other mental state 
assessment tests and mitochondrial pathology indicators in the other subgroups of 
the patients and in healthy controls. 
In order to identify relationships between a large numbers of mitochondrial 
pathology indicators in the research, a factor analysis was performed. We could 
distinguish four factors through principal component analysis with a Varimax 
rotation method. The characteristics of these factors are summarized in Tab. 10. 
Tab. 10. The characteristics of the mitochondrial pathology assessment factors in 
patients with bipolar disorder  
Factor No. Meaning 
Total variance 
explained, %  
Cumulative % of the 
explained variance  
1 3.62 30.17 30.17 
2 2.66 22.19 52.36 
3 2.27 18.87 71.23 
4 1.28 10.67 81.9 
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  The eigenvalues of all the factors were >1. The factor load for each of the 
mitochondrial pathology indicators allowing the evaluation of the correlation 
between picked factors and other indicators is shown as a factor loadings matrix 
where the highest values are shown in bold (Tab. 11). 
 
Tab. 11. Factor loadings matrix 
Mitochondrial 
function 
Factor 1 Factor 2 Factor 3 Factor 4 
Rotenone (p) .876 .015 -.063 .299 
Succinate (p) .860 .352 .288 .039 
ETSC (p) .821 .400 .237 .091 
ADP (p) .647 .507 .473 -.108 
Glutamate (p) .635 .380 .509 -.110 
ETSC .165 .938 .090 .068 
PR .228 .866 .175 .190 
DMP (p) .085 .175 .863 .141 
LEAK (p) .568 -.054 .602 .207 
IR (p) .389 .485 .586 .042 
Rotenone .238 .277 -.104 .730 
LEAK -.011 -.043 .373 .721 
PR – physiological respiration, LEAK – nonphosphorylating respiration measured after the 
addition of oligomycin, ETSC – electron transport system capacity measured after titration with 
uncoupler (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone, FCCP), IR – initial 
respiration in washed platelets before permeabilization with digitonin, DMP –respiration 
measured after the addition of digitonin+malate+pyruvate, ADP – stage 3 respiration supported 
through Complex I measured after the addition of ADP, Glutamate – stage 3 respiration 
measured after the addition of glutamate, Succinate – state 3 respiration supported through both 
Complex I and Complex II measured after the addition of the succinate,  Rotenone – respiration 
after Complex I inhibition measured after the addition of rotenone. (p) indicate permeabilized 
platelets. 
 
 According to the components distribution, Factor 1 is characterized by high 
values of: respiration after Complex I inhibition, stage 3 respiration supported 
through both Complex I and II, electron transport system capacity and stage 3 
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respiration supported through Complex I, all in permeabilized platelets. Factor 2 is 
characterized by high values of: electron transport system capacity and 
physiological respiration in intact platelets. Factor 3 is characterized by high values 
of:  initial respiration, respiration after addition of malate and pyruvate, and 
nonphosphorylating respiration, all in permeabilized platelets. Factor 4 is 
characterized by high values of:  respiration after Complex I inhibition and 
nonphosphorylating respiration in intact platelets. 
 We made the assessment of the differences between the experimental and 
control group based on the calculated values for each of the identified factors. The 
values of the four combined factors in the BPD patients and control groups were 
compared for that purpose (Tab. 12).  
Tab. 12.  The comparison of combined factors in patients with bipolar disorders 
and control group 
Groups 
Bipolar disorder Controls 
Combined factors 
 
Me Q1; Q3 Me Q1; Q3 
p 
Factor 1 (Rotenone (p), 
Succinate (p), ETSC (p), ADP 
(p), Glutamate (p)) 
-0.2 -0.95; 0.81 0.19 -0.56; 0.52 0.543 
Factor 2 (ETSC, PR) -0.13 -0.89; 0.28 0.34 -0.34; 1.19 0.024 
Factor 3 (DMP (p), Oligomycin 
(p), IR (p)) 
0.16 -0.59; 0.63 -0.32 -0.83; -0.06 0.023 
Factor 4 (Rotenone, LEAK) 0.15 -0.6; 1.05 -0.15 -0.7; 0.64 0.325 
Me – Mean; SD – Standard deviation; ; Q1 – Quartile 1; Q3 – Quartile 3; p – significance level . 
PR – physiological respiration, LEAK – nonphosphorylating respiration measured after the 
addition of oligomycin, ETSC – electron transport system capacity measured after titration with 
uncoupler (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone, FCCP), IR – initial 
respiration in washed platelets before permeabilization with digitonin, DMP –respiration 
measured after the addition of digitonin+malate+pyruvate, ADP – stage 3 respiration supported 
through Complex I measured after the addition of ADP, Glutamate – stage 3 respiration 
measured after the addition of glutamate, Succinate – state 3 respiration supported through both 
Complex I and Complex II measured after the addition of the succinate, Rotenone – respiration 




 The Mann-Whitney test shows that patients with bipolar disorder had 
significantly lower Factor 2 values than healthy controls (p=0.024) and 
significantly higher Factor 3 values than healthy controls (p=0.023). For patients 
with bipolar disorder we can expect a decrease in ETSC and physiological 
respiration in intact platelets, and a decrease in DMP, nonphosphorylation 
respiration and initial respiration in permeabilized platelets.  
 We also explored the duration period between the acute state and remission 
and its dependence on the mitochondrial pathology indicators in patients within 
different phases of bipolar disorder.  
 We calculated multiple linear regression equation for the patients in manic 
state (2): 
 
Trem = -56,3 + 2,1*XCS – 4,8*XCIV + 1745,1*XPR – 1475,4*XETSC + 386,5*XGlu




Trem – time period between the measurements (days),  
XCS – citrate synthase (nmol·min
-1
·mg-1),  
XCIV – Complex IV (nmol·min
-1
·mg-1),  
XPR – physiological respiration (pmol·sec
-1
·10-6 platelets),  
XETSC – electron transport system capacity (pmol·sec
-1
·10-6 platelets),  




The function was statistically valid (p=0.025), the Pearson correlation coefficient 
for the relationship between the mitochondrial function indicators and remission 
due date was rxy = 0.769, which shows a high closeness of relationships according 
to Chaddock scale. The regression model (2) explains 59.1% of the variance for the 
remission due date in patients with manic episode of the bipolar disorder.  
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There was no valid model showing the remission due date dependence of the 
mitochondrial function indicators for patients with a depressive episode of the 
bipolar disorder.  




The current study contributes to the research on the connection between 
pathophysiological processes in mitochondria and psychopathological symptoms 
in different mental disorders.  
One study was focused on finding biological markers of mitochondrial 
dysfunction measurable in peripheral blood (Fisar Z, Raboch J, 2008). Elements 
isolated from the peripheral blood, especially platelets and lymphocytes, are used 
to study changes in biochemical processes caused by mental disorders. Though 
mitochondrial pathology may not be similar across all brain regions and cell types, 
nor a number of neurochemical parameters, this is an acceptable model reflecting 
changes in the CNS because isolating blood platelets doesn’t require a complicated 
and invasive procedure. Affected mechanisms of the cellular compensation can 
lead to an increased ETS activity in lymphocytes as they provide the energy for the 
cell, and, in turn, a low platelet sensitivity may be expected (Feldhaus P et al, 
2011). 
We found that CI, CII and CS activity in BPD patients with mania and 
depression were not statistically different. These findings are in conjunction with 
results of previous investigations. Gubert made study where the activities of ETS 
complexes of mononuclear blood cells were examined in BPD patients in euthymic 
mood (Gubert C et al, 2013). No significant changes were found in complex I, 
complex II and complex II + III activities. The obtained results are also consistent 
with the data received by deSouza in 2014 which stated that mitochondrial 
complexes I-IV activity was not changed during the depressive episodes of BPD 
(deSouza RT et al, 2015). 
A decrease in COX activity was observed in BPD patients with depression 
and when compared with BPD patients with mania, the significance level was 
close to critical (Fig. 6). This data partially corresponds with the previous research 
made by Valla (Valla J et al, 2006) on the groups of patients with mild cognitive 
deficits (Alzheimer disease and other diseases), and data discovered by Fisar (Fisar 
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Z et al, 2016) for the group of patients with Alzheimer’s disease, where COX 
activity was decreased and negatively correlated with the Mini Mental State 
Examination (MMSE) score. This may lead to a suggestion that a decreased 
complex IV activity indicates cognitive impairment which is more evident during a 
depressive phase of the disease. Prince found a decrease in COX activity in the 
frontal cortex and caudate nucleus and linked it to an increased emotional and 
cognitive impairment in patients with SZ. In general (Prince JA et al, 2000), 
neurocognitive deficits are commonly associated with BPD (Aydemir O et al, 
2014) and they are often present in the very first episode (Bora E, Pantelis C, 
2015).  
Continuing the discussion of the changes in mitochondrial respiration in 
depressive phase of the disease we need to mention Gardner, who performed a 
research on mitochondrial enzymes activity and ATP production rate in patients 
with MDD and found an overall decrease in Complex I-IV in comparison with 
controls which correlated with the vulnerability to psychopathology in the 
following scales: ‘Somatic Anxiety’. ‘Psychasthenia’ and ‘Suspition’ (Gardner A 
et al, 2003).  
Correa found a decreased level of ETS complexes in an animal model of 
mania associated with manic symptoms (Correa et al, 2007). Freitas discovered an 
association between manic-like hyperactivity in a rat brain and a decrease in the 
activity of CS (Freitas TP et al, 2010). 
As seen from the results of the conducted analyses, in our research we didn’t 
find any significant correlation between certain psychometric scales and 
mitochondrial respiration indexes except for the correlation between Complex I 
and BPRS score in patients with mania. Based on the regression coefficient value, 
with the CI increase of 1 nmol*min-1mg-1 we expect a BPRS score increase of 0,7 
points. A low quantity of obtained correlations may be the result of the small 
amount of participants and further research in this area will provide us with the 
necessary data. 
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Research covering the association of mitochondrial enzymes activity and 
psychopathological symptoms of the BPD are limited while research exploring 
those connections in patients with other psychiatric diseases are widely present. 
Ben-Shakhar repeatedly obtained results indicating the connection between the 
severity of the SZ symptoms and mitochondrial impairment (Ben-Shachar D et al, 
1999, Ben-Shachar D et al, 2008) though there were no significant changes in the 
activity of complexes I and IV in mitochondria isolated from blood platelets of 
BPD patients in the same study. Dror et al. (2002) also performed a study 
exploring Complex I activity in schizophrenic and BPD patients and found that a 
degree of increase in complex I activity correlated directly with the severity of 
positive symptoms in patients with SZ (a tendency towards a negative correlation 
between complex I activity and negative symptoms did not reach statistical 
significance) (Dror N et al, 2002).  
As many psychopathological symptoms and mitochondrial pathology found 
in patients with SZ and BPD overlap (Clay H et al, 2011), those findings may 
highlight a connection between the severity of psychopathological symptoms and a 
specific and selective alteration in mitochondrial respiration in both diseases. 
Those alterations in energy metabolism may partially define or underlay 
psychopathology in a manic state or during the psychotic episode of the disease. 
Alterations may also vary according to the state of the disease, with the positive 
peak in manic states, which can be measured and proved statistically and negative 
peak in depressive states which is downplayed. Further studies are needed to verify 
this suggestion. 
Since Complexes I-IV play a key role in mitochondrial OXPHOS, their 
altered activity may reflect a mitochondrial dysfunction which, in turn, can result 
in impaired neuronal metabolism and neuronal plasticity expressed in certain 
psychopathological symptoms. Still there is not enough evidence whether this 
alteration is a causal or consequential effect of the disease. 
We found that there was no statistical difference in physiological respiration 
in all the subgroups (BPD patients with mania, BPD patients with depression, BPD 
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patients in remission, healthy controls). Therefore PR index cannot be used as 
biological marker sensitive to BPD. 
In the respiration rates there was a significant increase of LEAK index 
(nonphosphorylating respiration measured after the addition of oligomycin) both in 
intact and permeabilized platelets in the subgroup of BPD patients with mania 
compared to controls, though normalization for CS activity eliminated the 
difference. The LEAK respirations, as well as the flux control ratio LEAK/ETSC, 
are parameters characterizing mitochondrial damage. The flux control ratio 
LEAK/ETSC (i.e., oligomycin-inhibited respiration divided by uncoupled 
respiration at optimum FCCP concentration) in intact platelets remained very low, 
which indicated well-coupled mitochondria and the functional integrity of the inner 
mitochondrial membrane.  
Flux control ratio for the intact platelets (the ratio of a respiratory rate at a 
specific respiratory state divided to ETS capacity) was also significantly higher 
both in patients with BPD in a manic state and in a depressive state than in healthy 
controls. This may indicate an increased intrinsic uncoupling in the platelets of 
BPD patients and the availability of these parameters as indicators of the platelet 
respiration. 
Morris et al. (2017) postulates that symptomatically BPD is a biphasic 
disorder of energy ability; increased in mania and decreased in depression; and 
mitochondrial dysfunction may serve as a state dependent marker of the disorder 
with an increased mitochondrial function during mania and a decreased 
mitochondrial function during depression. The author offers a model explaining the 
biphasic nature of the disorder (Morris G et al, 2017). Our data partially 
corresponds with this postulate as the obtained data for the LEAK index increase 
and flux control ratio increase in patients with BPD seems to be mania-specific, 
though we did not obtain any data confirming a decrease of the same indexes 
during the depressive phase. 
Factor analysis in our study showed that patients with BPD had significantly 
lower Factor 2 values than healthy controls (ETS capacity and physiological 
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respiration in intact platelets) and significantly higher Factor 3 values than healthy 
controls (stage 3 respiration, nonphosphorylation respiration and initial respiration 
in permeabilized platelets).  
We speculate that a combination of those indexes with LEAK index and flux 
control ratio may serve as a clinical set of biological markers specific for the 
diagnosis of the bipolar disorder regardless of the phase of the disease.  
The current study also explores the duration period between the acute state 
and remission and its dependence on the mitochondrial pathology indicators in 
blood platelets of the patients with different phases of BPD. Indicators sensitive for 
the period length turned out to be: CS (positive values), COX (negative values), PR 
(positive values), ETS capacity (negative values), and respiration after the addition 
of glutamate (positive values).  
A possible connection between the illness duration and mitochondrial 
dysfunction in patients with BPD was also studied by Chang, who found a negative 
correlation between NAA/Creatine + Phosphocreatine or NAA levels and illness 
duration. However, later studies found that decreased NAA levels was restricted to 
the basal ganglia of the brain (Chang K et al, 2003). Berk proposed a general role 
of mitochondrial dysfunction in the disease progression (Berk M et al, 2011). 
Discemibly there is no suggested clinical test for a combination of the 
mitochondrial impairment indicators for the BPD, and therefore the data obtained 
from the current research may serve as an easily-accessible set of predictors for the 
episode duration in clinical practice. 
There are few research findings confirming the role of mitochondrial 
respiration in the severity of the clinical symptoms of BPD (Scaini G et al, 2016). 
A body of evidence for the increased mitochondrial respiration and ATP 
production in a manic phase and decreased mitochondrial function in patients in 
the euthymic or depressive phase of the BPD was found, though the research data 
are partially controversial (Hroudova J, Fisar Z, 2011). It has yet to be discovered 
whether the impairment in mitochondrial function contributes to the disease 
process or is an independent process. 
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Various mitochondrial function alterations in patients with BPD do not 
indicate the same behavioral changes or psychopathological symptoms regardless 
of the tissue type or brain area. We suggest that the same mitochondrial 
impairment needs to be present in certain brain areas involved in certain clinical 
symptoms of the disease. Bioenergetic demand of the brain cells may vary in 
different brain areas and this demand is sensitive to different factors, which means 
that there is a certain threshold value of damaged mitochondria causing a symptom 
available for clinical measurement, and this value may be different for different 
neurons. These differences might enable some psychopathological symptoms to 
manifest while other symptoms remain hidden. 
Explored abnormalities in mitochondrial function may reduce the cell ability 
for the appropriate stress response to such stimuli as emotional outbursts (an 
increased glutamate release), starvation (decreased glucose levels) and other risk 
factors known for psychotic episodes in affective disorders such as in-utero and 
infant malnutrition, substance abuse, and traumatic experiences (Kroll JL, 2007). 
If we suggest that the obtained abnormalities in platelet mitochondrial 
respiration are similar to the abnormalities in brain mitochondrial respiration, it 
may further confirm the contribution of energy metabolism impairment to the 
pathophysiology of BPD. Given the lack of a reliable and clinically relevant 
biological markers for BPD and other mood disorders, a set of mitochondrial 
enzymes activity and respiration rates easily obtained from peripheral blood 
platelets might become a useful clinical tool in the diagnostic process.  
A unique combination of the factors above in further studies may help to 
understand the effect of the certain mitochondrial function alteration on specific 
behaviors and psychopathological symptoms. Regardless of the rank of the certain 
index in the sequence of disease-causing events, an overall mitochondrial 






BPD is a complex disease that involves several biological pathways. 
Mitochondrial dysfunction was included when the mitochondrial hypothesis of 
BPD was firstly proposed by Kato in 2000. Since then it was supported by various 
data including decreased ATP production, upregulation of genes involved in 
apoptosis, downregulation of mitochondrial genes regulating OXPHOS, decreased 
antioxidant defences, abnormalities in the structure, and distribution of 
mitochondria and others. Some of the pathophysiological processes in BPD were 
discovered to be associated with certain clinical symptoms of the disease such as 
cognitive impairment, hyperactivity and others.  
The main research question in the conducted study was whether energy 
metabolism in mitochondria corresponds to clinical evaluation of the 
psychopathological symptoms in patients with bipolar disorder.  
The results obtained by the current study: 
- support Hypothesis 1 that there is a set of mitochondrial functional 
impairment indexes specific for the current phase of the disorder. For patients with 
BPD we can expect a decrease in ETSC and physiological respiration in intact 
platelets, and an increase in DMP, nonphosphorylation respiration and initial 
respiration in permeabilized platelets. Healthy controls do not show this type of 
mitochondrial alteration. Obtaining peripheral blood platelets from patients with 
mental disorders is an easy and quick procedure which may be useful for in vivo 
studies of mitochondrial respiration in psychiatric diseases; 
- support Hypothesis 2 that the severity of the symptoms of BPD is 
associated with the severity of the alteration of the mitochondrial function. A 
significant correlation was observed between Complex I and BPRS score in 
patients with manic symptoms; 
- do not support Hypothesis 3 that there is a difference in the levels of 
mitochondrial respiration and enzyme activity in manic state and depressive state. 
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There was no significant difference in mitochondrial respiration and enzymes 
activity between subgroups of BPD patients in mania and depression. 
- support Hypothesis 4 that there is a difference in the levels of 
mitochondrial respiration and enzyme activity in patients with BPD and healthy 
controls both in acute state and remission. LEAK index both in intact and 
permeabilized platelets was significantly higher in BPD patients with mania than in 
controls; flux control ratio (the ratio of a respiratory rate at a specific respiratory 
state divided to ETSC) was significantly higher in patients with mania than in 
controls and in patients with depression than in controls; in intact platelets, the 
LEAK index was significantly higher in BPD patients with remission than in 
healthy controls.  
Additional results of the study include the exploration of the duration period 
between the acute state and remission and its dependence on the mitochondrial 
pathology indicators in patients with different phases of BPD. Indicators sensitive 
for the period length turned out to be: CS (positive values), COX (negative values), 
PR (positive values), ETS capacity (negative values), and respiration after the 
addition of glutamate (positive values).  
Taken together, the obtained data provide evidence for the connection 
between psychopathological symptoms and mitochondrial function in mental 
disorders through cellular mechanisms involved in the pathology of BPD explored 
in the current study.  
Results from this study provide information for clinicians and other 
researchers. This study also portrays mitochondria as a promising targets for the 
therapeutic modulation of cellular resilience and synapses in neuronal pathways 
involved in high-order functions of the brain in different mental disorders, 
including BPD.  
Further research focused on treatment of this disorder, therapeutic strategies 






ADP - adenosine diphosphate 
AIF – apoptose inducing factor 
AMP - adenosine monophosphate 
ANOVA - one-way analysis of variance 
ATP – adenosine triphosphate 
BBB - blood–brain barrier 
BDNF – brain-derived neurotrophic factor 
BPD – bipolar disorder 
BPRS – Brief Psychiatric Rating Scale 
CGI-I - Clinical Global Impression - Improvement scale 
CNS – central nervous system 
CNTF - ciliary neurotrophic factor  
CoA – coenzyme A 
COX – cytochrome c oxidase or complex IV 
CPEO - chronic progressive external ophtalmoplegia 
CREB – cyclic AMP response element-binding protein  
CS – citrate synthase 
CSF - cerebrospinal fluid 
DMP – digitonin+malate+pyruvate 
DNA - deoxyribonucleic acid 
ER - endoplasmic reticulum  
ETS – electron transport system 
ETSC – electron transport system capacity 
FAD - flavin adenine dinucleotide 
FADH2 - flavin adenine dinucleotide, reduced form 
FCCP - carbonylcyanide p-triflouromethoxyphenylhydrazone 
FMN - flavinmononukleoktid 
fMRI - Functional magnetic resonance imaging  
 113 
FRTA - free radical theory of aging 
GDNF - glial cell line-derived neurotrophic factor ( 
GTP - guanosine-5'-triphosphate 
HPA - hypothalamic–pituitary–adrenal  
IGF-1 - insulin-like growth factor 1  
IR – initial respiration 
IVF – in vitro fertilization 
KSS - Kearns–Sayre syndrome 
LHON - Leber hereditary optic neuropathy 
LNGFR - low-affinity nerve growth factor receptor  
LS - Leigh syndrome 
MADRS - Montgomery–Åsberg Depression Rating Scale 
MAO – monoamine oxidase 
MD - mitochondrial disease 
MDD – major depressive disorder 
MDQ – Mood Disorder Questionnaire 
MELAS - mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes 
MERRF - myoclonic epilepsy with ragged-red fibers 
MIDD - maternally inherited diabetes and deafness 
MMSE – Mini Mental State Examination 
MPT - mitochondria permeability transition 
mtDNA - mitochondrial DNA 
NAA -  N-acetylaspartate 
NAD+ - nicotinamide adenine dinucleotide, oxidized form 
NADH - nicotinamide adenine dinucleotide, reduced form 
NADP+ - nicotinamide adenine dinucleotide phosphate 
NAPR - neuropathy, ataxia, and retinitis pigmentosa 
nDNA - nuclear DNA 
NGF - nerve growth factor  
NT-3 - neurotrophin-3  
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NT-4 - neurotrophin-4 
OXPHOS - oxidative phosphorylation 
pH - potential of hydrogen 
PR – physiological respiration 
RCR - respiratory control ratio 
RNA - ribonucleic acid 
ROS – reactive oxygen species 
SNHL - sensorineural hearing loss 
SZ - schizophrenia 
TCA – tricarboxylic acid cycle 
Trk -  tropomyosin receptor kinase  
UK – United Kingdom 
VEGF - vascular endothelial growth factor  
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